



## THE ARTHRITIS RESEARCH CANADA BOARD MEETING – THURSDAY, SEPTEMBER 5, 2019 ANNUAL REPORT OF THE SCIENTIFIC DIRECTOR

### SUMMER STUDENTS

**Iman Sheriff** (Supervisor: **Diane Lacaille**) completed a summer studentship at Arthritis Research Canada Richmond. Ms. Sheriff received a \$4,000 Canadian Rheumatology Association Summer Studentship award. Ms. Sheriff worked with Team Lacaille on the project titled *'Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of complications in people with inflammatory arthritis'*.

**Emile Pianarosa** (Supervisors: **Cheryl Barnabe** and **Glen Hazlewood**) was a summer student at Arthritis Research Canada Calgary. Emile received a Canadian Institutes of Health Research Institute of Musculoskeletal Health and Arthritis Undergraduate Summer Studentship Award of \$5,000. Her project was *'Addressing equity considerations in the Canadian Rheumatology Association Rheumatoid Arthritis Guidelines'*. This work will ensure that the 2012 treatment guidelines and those under development minimize inequities in treatment of patients from disadvantaged populations.

**Jamie Park** and **Enav Zusman** completed summer studentships at Arthritis Research Canada Richmond (Supervisor: **Mary De Vera**). Both students received the Canadian Institutes of Health Research Summer Studentship award of \$5,000 each. Ms. Park's project was *'A qualitative descriptive study of Reddit forums to explore the experiences and information needs of individuals with arthritis and comorbid mental disorders'* and Ms. Zusman's project was *'Epidemiology of mental health complications in pregnant and postpartum women with rheumatoid arthritis: a systematic review'*.

**Kiran Dhiman** (Supervisor: **Diane Lacaille**) who was a summer student at Arthritis Research Canada in 2018 received a \$300 Poster Day Award from the School of Public Health at the University of Saskatchewan for her poster *"A qualitative study exploring relevance of the Making it Work program to osteoarthritis"*. Ms. Dhiman also received a \$300 and \$350 Travel Awards from the University of Saskatchewan to present the poster at the Canadian Rheumatology Association annual meeting in Montreal in February.

### TRAINEES

**Lulu Guo** (Supervisor: **Hui Xie**) became a new Arthritis Research Canada trainee in the Faculty of Health Sciences at Simon Fraser University funded through a grant to Dr. Xie by the National Sciences and Engineering Research Council of Canada. Her project is titled *"Statistical approaches to improve the power and robustness in method effectiveness estimation in real world clinical trials."*

**Valerie Umaefulam** (Supervisor: **Cheryl Barnabe**) became a new Arthritis Research Canada trainee at the University of Calgary. Valerie will complete a two year postdoctoral fellowship. Her project title is “*Shared decision making with Indigenous peoples*”.

## **TRAINEE SALARY AWARDS & SCIENTIFIC AWARDS**

Four Arthritis Research Canada Trainees were awarded competitive Arthritis Research Canada/Lilly Early Rheumatology Researcher Travel Scholarships to attend the 2018 National Meetings of the American College of Rheumatology in Chicago. **May Choi** (Supervisors: **Deborah Marshall** & Marv Fritzier) presented four papers. **Graham MacDonald** (Supervisor: **Linda Li**) was a co-author with Arthritis Patient Alliance Board member **Kelly English** on a paper in a new ‘Patient Category’. **Jenny Leese** (Supervisor: **Linda Li**) presented one abstract. **Alyssa Howren** (Supervisor: **Mary De Vera**) attended her first ACR meeting and was first author on two abstracts and co-author on another two.

**Elena Lopatina** (Supervisors: **Deborah Marshall** and **Claire Barber**) was awarded the Arthritis Alliance of Canada PhD Student Award of \$750.00.

**Scott Brunet** (Thesis Committee Member: **Cheryl Barnabe**) is a Master’s student at the McCaig Institute. Scott was awarded the Arthritis Alliance of Canada Master’s Student Award of \$750.00.

Another three Arthritis Research Canada Trainees received the Arthritis Research Canada/Lilly Early Rheumatology Researcher Travel Scholarships to attend the 2019 European League Against Rheumatism (EULAR) meeting in Madrid, Spain in June. **Kiana Yazdani** (Supervisor **Diane Lacaille**) presented three abstracts, one an oral presentation. **Alyssa Howren** (Supervisor: **Mary De Vera**) presented one abstract, and **Mohammad Atiquzzaman** (Supervisor: Aslam Anis) presented one abstract, also an oral presentation.

**May Choi** (Supervisors: **Ann Clarke**, Marv Fritzier) was awarded the very prestigious Lupus Foundation of America Gary S. Gilkeson Career Development Award (\$70,000 USD x 2 years). She will complete an MPH at Harvard under the mentorship of Karen Costenbader and will work primarily on a project entitled “*LEAAPPS: Longitudinal Examination of ANA Associations, Prevalence, and Performance in SLE*” and will then be returning to the University of Calgary.

**May Choi** was also awarded the 2019 Canadian Rheumatology Association Award for Best Abstract on Research by a Rheumatology Resident and **André Luquini** (Supervisor: **Diane Lacaille**) was awarded the 2019 Canadian Rheumatology Association Award for Best Abstract by a Rheumatology Post-Graduate Research Trainee.

Arthritis Research Canada Calgary Trainee **Darren Mazzei** (Supervisor: **Deborah Marshall**) was awarded a 2019 University of Calgary Cumming School of Medicine Graduate Scholarship of \$30,000/year over four years. His project title is 'Cost effectiveness analysis and budget impact assessment of the GLA:D Canada pilot study in Alberta community rehabilitation clinics'.

**Shahrzad Salmasi** (Supervisor: **Mary De Vera**) became a new Arthritis Research Canada Trainee working on a PhD project titled "Towards a core outcome set for medication adherence research in rheumatology" then she received an Association of Faculties of Pharmacy of Canada (AFPC) Pharmacy Practice Research Award which recognizes an outstanding pharmacy graduate student.

**Flora To-Miles** (Supervisor: **Catherine Backman**) is recipient of the 2018 Arthritis Health Professions Association-Arthritis Society Grant Competition for her study "The health promoting potential of social and creative activities: An exploratory study of adults with and without inflammatory arthritis." The \$5000 grant will contribute to Flora's thesis project examining how social activities (doing things with or for others) and creative activities (making or designing projects) are associated with health outcomes.

**Clayon Hamilton** (Supervisors: **Linda Li** and **Shannon Holmes**) has received a Canadian Institutes of Health Research Health System Impact Fellowship Award (\$70,000/year x 2 years plus \$7,500/year training and research allowance). Dr. Hamilton's project, "Patient/Public Engagement Measurement and Evaluation Project" will be based within the BC Ministry of Health's Patients as Partners Initiative. He will develop and evaluate quality indicators of patient engagement in health policy decisions. The ultimate goal is to improve the quality of the Patient as Partners Initiative in BC.

## **FACULTY**

In July The Arthritis Research Canada/Arthrite-recherche Canada Board of Directors approved the appointment of six additional scientists.

**Susanne Benseler** joined Arthritis Research Canada Calgary as an expert in Childhood arthritis and our first scientist specializing in childhood arthritis.

**Laëtitia Michou** joined Arthrite-recherche Canada Laval as an internationally recognized expert on bone disease including diseases like osteoporosis (e.g., the cause of hip fractures) as well as genetics of autoimmune diseases.

Finally, four new scientists were appointed as part of a new Arthritis Research Canada centre created at McGill University. The four new McGill scientists are **Michal Abrahamowicz, Marie Hudson, Deborah Da Costa, and Susan Bartlett**. Dr. Abrahamowicz is the James McGill Professor of Biostatistics and the Canadian, and a world, pioneer in biostatistics for arthritis and chronic disease in general. Dr. Hudson has a longstanding interest in autoimmune diseases such as scleroderma and inflammatory muscle disease. Dr. Da Costa brings substantial research experience in health psychology including studies of the role of stress, depression, fatigue (both mental and physical), and sleep quality on overall health status in arthritic diseases. Dr. Bartlett has evaluated extensively the role of behaviours (e.g., diet, smoking, exercise) and psychosocial factors (e.g., stress, depression) on how people with arthritis do.

### **Honours**

**Deborah Marshall** has been awarded the 2019 Canadian Agency for Drugs and Technologies in Health Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment. This award recognizes individuals whose outstanding achievements have significantly advanced the fields of health technology assessment, evidence-based drug reviews, or optimal technology utilization in Canada.

**Mary De Vera** has been awarded a New Investigator Research Award from the Association of Faculties of Pharmacy of Canada. The candidates for this annual award must be involved in high quality research in pharmacy as an independent principal investigator, which includes the supervision of graduate students and/or postdoctoral fellows.

**Diane Lacaille** was awarded the 2019 Canadian Rheumatology Association Distinguished Investigator Award at the recent Canadian Rheumatology Association Annual Meeting in Montreal. The award is the top award for science from the organization and acknowledged her huge contributions to closing the treatment gap for people with rheumatoid arthritis and her unique project to actually prevent work disability from occurring in people with inflammatory arthritis.

**Glen Hazlewood** was awarded the 2019 Canadian Rheumatology Association Emerging Investigator Award. The award recognizes the young investigator who is making a major contribution to arthritis research. Dr. Hazlewood has already had multiple research grants from the Canadian Institutes of Health Research to pursue topics including patients' preferences in treatment decision making.

**Aslam Anis** was awarded a Distinguished Achievement Award, by the Faculty of Medicine at the University of British Columbia. Dr. Anis also received the Research and Mission award from the Providence Health Care Research Institute and Providence Health Care.

**Cheryl Barnabe** has been awarded a \$10,000 Canadian Institutes of Health Research 2018-2019 Killam Emerging Research Leader Award.

**Cheryl Barnabe** and **Diane Lacaille** have been appointed members of the Canadian Institutes of Health Research Institute of Musculoskeletal Health and Arthritis Advisory Board effective September 1, 2018. The term is three years, renewable for an additional three years.

**Cheryl Barnabe** has also been appointed Vice-Chair, Department of Medicine, Office of Indigenous Health, University of Calgary/Alberta Health Sciences, and in addition Dr. Barnabe was awarded a Team Builder of the Year Award from the Department of Medicine, University of Calgary/Alberta Health Services.

**Catherine Backman** was elected President, Canadian Association of Occupational Therapists. She serves a two-year term as President and Chair of the Board of Directors, October 1, 2018 to September 30, 2020.

**Nick Bansback** was awarded the Arthritis Alliance of Canada Knowledge Translation Science/Research Award of \$750.

Arthritis Patient Advisory Board Member **Alison Hoens** who is currently working out of Arthritis Research Canada in her role with the Knowledge Translation Methods Cluster of the BC SPOR SUPPORT Unit has been awarded the most prestigious honour awarded by the Canadian Physical Therapy Association. She is the 2018 recipient of the Enid Graham Memorial Lecture Award. As winner of the award Alison presented a lecture at the Canadian Physical Therapy Congress in Montreal on November 2, 2018.

## **SALARY AWARDS**

**Paul Fortin** of Arthrite-recherche Canada Laval has been awarded a renewal of his Canadian Institutes of Health Research Tier 1 Canada Research Chair titled “*Systemic autoimmune rheumatic diseases*” (lupus, Sjogren’s, systemic sclerosis, vasculitis and others). The award is \$200,000 a year for seven years (total - \$1.4M).

**Cheryl Barnabe** was awarded a 5-year Tier II Canada Research Chair from the Canadian Institutes of Health Research titled ‘*Rheumatoid arthritis and autoimmune diseases.*’ This provides \$500,000 over the 5-years towards her university salary. In addition, the President of the University of Calgary has awarded Dr. Barnabe \$88,000 of the \$100,000 per year as an operating grant to develop and conduct new research programs in indigenous health.

## **SCIENTIFIC AWARDS**

**Diane Lacaille** is a Co-Investigator on a 3-year \$1.5 M Grant from Employment and Social Development Canada - Opportunities Fund for Persons with Disabilities – Working with Employers. The grant title is *'Harnessing talent: alliance for recruiting and retaining Canadians with disabilities'*. The Principal Investigator is Marc White of the Work Wellness and Disability Prevention Institute.

**Antonio Aviña** and **John Esdaile** are the Co-principal investigators on a five year \$707,625 Canadian Institutes of Health Research grant entitled *"Risk of retinal toxicity in patients with systemic lupus erythematosus and rheumatoid arthritis on long-term hydroxychloroquine therapy"*. Co-Investigators on the project include **Hyon Choi, Linda Li, Kam Shojanja, Diane Lacaille, Hui Xie**, David Maberley, Mahyar Etminan and Martin Dawes.

**Deborah Marshall** is the Principal Investigator on a three year \$283,051 Canadian Institutes of Health Research grant entitled *"Towards a patient-centered system: Integrating preferences of patients with osteoarthritis into evaluation of health services interventions to improve patient outcomes and health system efficiency"*. Co-Investigators include **Claire Barber**, Eric Bohm, Peter Faris, **Glen Hazlewood**, Jean Miller, Tom Noseworthy, George Tomlinson, Colleen Weeks and Jason Werle.

**Michael Hunt** is the Principal Investigator on a five year \$677,025 Canadian Institutes of Health Research grant for their project: *"Linking biomechanical and imaging outcomes to better understand the effects of running on knee joint health"*. Co-Investigators include **Jean-Francois Esculier** (Supervisor: **Michael Hunt**), Alex Rauscher, Jack Taunton and David Wilson.

**Paul Fortin** is the Principal Investigator on a three year \$416,280 Canadian Institutes of Health Research grant for his project *"Mapping anti-mitochondrial antibodies in systemic lupus erythematosus"*. Co-Investigators are **Michal Abrahamowicz**, Eric Boilard and Joyce Rauch.

**Claire Barber** has received the Department of Medicine, Cumming School of Medicine Clinical Analytics Award, a one year \$50,000 grant from the University of Calgary, for her project *"Development of a patient-centered rheumatoid arthritis (RA) quality of care survey and testing continuous reporting of established RA quality measures"*.

**Antonio Aviña**, along with Co-Investigators **John Esdaile, Diane Lacaille** and **Kam Shojanja** has been awarded a 1-year \$20,000 Planning Grant from the Canadian Institutes of Health Research for his project *'Towards improving screening of retinal toxicity of hydroxychloroquine inpatients with systemic lupus erythematosus and rheumatoid arthritis'*.

**Jan Dutz** is the Principal Investigator on a team who will create the “*Dermatology Rheumatology Educational Tool for Autoimmune Manifestations, the DREAM TOOL.*” This is a one year \$10,000 USD award. Other team members include **Kam Shojan**, and **Marie Hudson**. They received the award for their inaugural project titled

**Paul Fortin, Deborah Da Costa** and Josée Savard are Co-Principal Investigators on a one-year \$100,000 Canadian Institutes of Health Research Project Grant titled “*Impact of internet delivered cognitive behavioral therapy for insomnia in persons with systemic lupus erythematosus: a randomized clinical trial*”. Elham Rahme is a Co-Investigator. They will determine whether cognitive behavioural therapy will reduce insomnia and other commonly experienced symptoms in lupus, including fatigue, depression and pain compared to usual treatment.

**Cheryl Barnabe** is a Co-Investigator on a \$10,000 Canadian Institutes of Health Research Planning and Dissemination Grant entitled “*Moving from the bench to clinical trials: facilitating uptake of technological innovation in High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) for clinical research in inflammatory arthritis*”.

**Cheryl Barnabe** is a Co-Principal Investigator or Co-Investigator on five successful Canadian Institutes of Health Research Grants. Four of the five are related to Indigenous Health:

- 1) **Dr. Barnabe** is a Co-Investigator along with **Deborah Marshall** on a Canadian Institutes of Health Research seven-year \$1,039,450 grant titled “*SHRed Injuries: preventing injuries and their consequences in youth sport and recreation*”, Principal Investigator: Carolyn Ann Emery. SHRed stands for “surveillance in High Schools to reduce injuries. SHRed will promote a healthy and active future for youth through research on injury prevention in youth sport and recreation, to reduce the public health burden of sport and recreation injuries and their consequences.
- 2) Co-Principal Investigator with Cara Babits, Lynden Crowshoe, Michael Green, Rita Henderson, Charles Leduc, Stephanie Montesanti, Adam Murry and Esther Tailfeathers on a \$75,000 one year grant titled “*Indigenous health Equity Network for Primary Health Care and Policy Research in Alberta*”. It brings together primary care providers and leaders, health systems and policy researchers, and Indigenous community leaders and members, with the goal of building a strong primary health care system to reduce health care inequities experienced by Indigenous people;
- 3) Co-Investigator on a \$75,000 one year grant titled “*Sites of Survivance Network: Survival, resistance and resurgence of Indigenous health and well-being*”. Research does not always honour Indigenous perspectives and knowledge. The Sites of Survivance Network will frame Indigenous health research within three broad streams: survival, resistance, and resurgence. By engaging in this framework, researchers will be able to weave together Indigenous ways of knowing, western biomedical perspectives, and agency within Willie Ermine’s ethical space of knowing, to create a ‘third space’ of knowing;

- 4) Co-Investigator on a one-year \$75,000 grant titled *“Indigenous Wellness Environment NEIHR Network: A NEIHR Network with a focus on Indigenous Wellness”*. The Indigenous Wellness Environment will work closely with Indigenous communities in their wellness journeys, learning from their leadership and wisdom awakening/re-awakening. Guiding principles and wise practices for Indigenous wellness will be created.
- 5) Co-Investigator on a three-year \$184,875 grant titled *“Understanding and defining quality of care in the emergency department with First Nations members in Alberta”*. Administrative data will be used to document quantitative differences in emergency department patient visit data between First Nations and non-First Nations populations. Qualitative and Indigenous methodologies will be used to understand emergency department care and experiences for First Nations patients. The team will also produce First Nations definitions of quality of emergency department care.

**Hui Xie** is the Principal Investigator on a \$100,000 two-year Award from the BC Support Unit. The project is titled *“Improving the efficiency and robustness of statistical inference for patient-oriented treatment effect in real-world clinical trials”*. Co-Investigators include Joan Hu, Ehsan Karim, **Diane Lacaille**, **Linda Li**, Yi Qian and Hubert Wong.

**Deborah Da Costa** is the Principal Investigator on a \$260,000 three-year Canadian Institutes of Health Research Project Grant Titled *“Fathers matter: a prospective study to identify determinants of fathers' engagement during pregnancy”*. Co-investigators on the project are Francine deMontigny, **Michal Abrahamowicz**, Christine Gervais, Samir Khalife, Tuong-Vi Nguyen, Tamarha Pierce and Phyllis Zelkowitz.

**Jackie Whittaker** is a Co-Investigator (Principal Investigator: Jordan Miller) on a four-year \$1,403,776 Canadian Institutes of Health Research grant titled *“Determining the impact of a physiotherapist-led primary care model for low back pain - A cluster randomized controlled trial”* Other Co-I's on the award are David Barber, Lynn Cooper, Catherine Donnelly, Simon French, Michael Green, Jonathan Hill, Joy Macdermid, Jacquelyn Marsh, Colleen McPhee, Kathleen Norman, Julie Richardson, Garry Salisbury, Monica Taljaard, and Timothy Wideman.

**Marie Hudson** is the Principal Investigator on a 2.5 year Canadian Institutes of Health Research award titled *“Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis”* Co-Investigators include Sabrina Hoa, Mireille Schnitzer, Pierre Laneuville, Linda Peltier, and Matthieu Resche-Rigon.

Mahyar Etminan and **Antonio Aviña** are Co-Principal Investigators on an \$187,000 three-year award from the Canadian Institutes of Health Research award titled *“Tumor necrosis factor inhibitors and risk of multiple sclerosis”*. The Co-Investigators are Helen Tremlett, Gil Kaplan, **Diane Lacaille**, Ruth-Ann Marrie, Juan Nicholas Pena-Sanchez, Laura Targownik, Regina Taylor-Gjevrr and **Hui Xie**.



**Claire Barber** and **Glen Hazlewood** are Co-Principal Investigators on an \$119,700 two-year Canadian Rheumatology Association grant titled *“Optimizing early treatment in early rheumatoid arthritis through shared decision-making”*. Co-investigators on this project include **Nick Bansback**, **Linda Li**, Dianne Mosher, Laurie Proulx and Dawn Richards.

**Mark Harrison** is the Principal Investigator on a \$66,655 one-year Canadian Rheumatology Association grant titled *“Perspectives on the implementation of a nursing educator fee code for community-based patients with rheumatic disease in BC (RHEUM-NURSE)”*. Co-Investigators include Michelle Teo, Sarah Munro, **Mary De Vera**, Jason Kur, **Cheryl Koehn**, Patricia Patrick, **Kam Shojan** and Magda Aguiar.

**Mary De Vera** as Principal Investigator has received a \$58,238 one-year Canadian Rheumatology Association grant titled *“Making medication decisions for family planning and pregnancy among women with rheumatoid arthritis (MOTHERS)”*: Co-Investigators are Neda Amiri, Corrie Baldwin, Stephanie Ensworth, **Glen Hazlewood**, **Nevena Rebic** and Laurie Proulx.

Signed:



---

John M. Esdaile, MD, MPH, FRCPC, MAHS  
Scientific Director, Arthritis Research Canada

## Appendix I

### FUNDING FROM JULY 1, 2018 TO JUNE 30, 2019

AIHS - Alberta Innovates Health Solutions; CAN - Canadian Arthritis Network; CIORA - Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR - Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; CHHM - Centre for Hip Health and Mobility; HSFC - Heart and Stroke Foundation of Canada; EULAR - European League Against Rheumatism; MSFHR - Michael Smith Foundation for Health Research; NCI - National Cancer Institute; NIH - National Institutes of Health; NCE - Networks of Centres of Excellence; TAS - The Arthritis Society;; UBC - University of British Columbia; SPARTAN - Spondyloarthritis research and treatment network ; SRCC - Spondyloarthritis Research Consortium of Canada

### SCIENTIST FUNDING - Operating Grants

Funding Agency	Title	PI(s)	Co-I(s)	Annual Amount	Total Awarded	Start Date	End Date
CIHR	The pricing of generic drugs and its impact on market structure, competitiveness and security of supply	<b>Anis A</b>	P Grootendorst, A Hollis, C Ingram, L Lynd, W Zhang	\$80,325	\$240,975	Apr-17	Mar-20
CIHR/SPOR Support Units/BC SUPPORT	Support for People and Patient-Oriented Research and Trials (SUPPORT) - CHEOS	<b>Anis A</b>		\$329,384	\$1,646,920	Nov-16	Oct-21
CIORA	Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis	<b>Avina-Zubieta A</b>	<b>C Barber, J Esdaile, LC Li, O Tseng, H Xie, M Dawes, B Hobson, C Koehn, J Kur, L Nasmith, K Shojania, S Singh</b>	\$47,500	\$95,000	Jul-18	Jun-19
10K from SPARTAN and 10K from SRCC	Validation of administrative billing codes for the diagnosis of axial spondyloarthritis	<b>Avina-Zubieta A, Chan J</b>	A So	\$20,000	\$20,000	May-18	Apr-19
CIHR	Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy	<b>Avina-Zubieta A</b>	<b>H Choi, M Dawes, M Etminan, D Lacaille, LC Li, D Maberley, K Shojania, H Xie</b>	\$141,525	\$707,625	Mar-19	Feb-24
CIORA	Bringing patients and therapies together sooner: building clinical trial capacity in myositis to facilitate early access to treatments and improved outcomes	<b>Hudson M</b>	<b>Avina-Zubieta A, Fortin P</b>	\$60,000	\$120,000	Oct-17	Sep-19

CIHR	Improving access to medicines in Canada and abroad	Law M	<b>N Bansback</b> , L Goldsmith, <b>M Harrison</b> , AM Holbrook, S Majumdar, M Mamdani, S Wong	\$89,214	\$624,498	Jul-16	Jun-23
CIHR	Design for better health: user-centred design and evaluation of interactive media for health education, communication and decision-making	Witteman H	J Ancker, P Archambault, <b>N Bansback</b> , MD Beaulieu, J Bender, J Bettinger, C Chambers, D Chan, H Colquhoun, S Desroches, et al	\$8,510.40	\$544,538	Jul-16	Jun-21
CIHR	Development of a patient-centered balanced scorecard approach to improve quality of care in rheumatoid arthritis patients in Canada	<b>Barber C, Lacaille D</b>	<b>C Barnabe, G Hazlewood</b> , J Homik, <b>L Li</b> , P MacMullan, <b>DA Marshall</b> , D Mosher, J Rankin, K Then, <b>K English, K Tsui</b>	\$91,800.00	\$183,600	Apr 17	Mar 19
CIHR	Arthritis Care for Indigenous Populations'	<b>Barnabe C</b>	<b>D Marshall</b> , S Bernatsky, L Lis, W Maksymowych, V Bykerk, <b>G Hazlewood</b> , J Jull, L Crowshoe et al	\$115,000	\$575,000	Jul-15	Jun-20
CIHR	Alberta Indigenous Mentorship in Health Innovation Network (AIM-HI Network)	<b>Barnabe C</b> , Healy B, Tailfeathers E, Crowshoe L, Currie C, Fellner k, Henry R, Voyageur C	R Weasel Fat, J Baker, B Bastien, S Chisan, A Greenshaw, R Henderson, A Kennedy, S Kutz, <b>A Loyola-Sanchez</b> , L ManyGuns, T Oosterbroek, M Rock, W Shotyk	\$200,000	\$1,000,000	Apr-17	Mar-22

CIORA	An initiative to address Indigenous patient and community educational needs in rheumatic diseases	<b>Barnabe C, Loyola-Sanchez A</b>	T Bear Chief, V Bear Chief, C Brough, S Calf Robe, L Crane, L Crowshoe, R Greenslade, R Henderson, T Linkert, B Little Chief, H Melting Tallow, S Samanani, T Scalplock, C Sorensen, T White	\$57,500	\$115,000	Jul-18	Jun-20
CIHR	IDEATE (InDigEnous heAlTh Equity) Network for primary health care and policy research in Alberta	<b>Barnabe C, Bablitz C, Crowshoe L, Green M, Henderson R, Leduc C, Montesanti S, Murry A, Tailfeathers E</b>	J Auger, W Austen, L Bastien, N Cardinal, H Crowshoe, S Funnell, L Green, B Healy, R Henry, M Landrie, J Leason, R Littlechild, N McRee, M Potestio, S Samanani, C Sarin, E Toth, M White	\$75,000	\$75,000	Oct-18	Sep-19
CIHR	Brain dysfunction in chronic inflammatory disease: reciprocal effects of CNS and periphery crosstalk	Swain M	<b>C Barnabe, B Goodyear, S Hirota, G Kaplan, G Macqueen, E Mayer, R Myers, Q Pittman, K Sharkey</b>	\$8,364.20	\$335,646	Jul-14	Jun-19
Rheumatology Research Foundation Innovative Research Award	Effect of the DASH diet on serum uric acid in gout patients	<b>Choi H</b>		\$249,750.00	\$499,500	Jul-17	Jun-19

CIHR	Development and validation of a new method for measuring cartilage load using upright open Magnetic Resonance Imaging (MRI)	Wilson D	<b>J Cibere</b>	\$118,500	\$474,000	Jul-16	Jun-20
CIHR	Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes	<b>Cibere J</b>	<b>J Esdaile, B Forster, J Kopec, L Li, D Wilson, H Wong,</b>	\$177,225	\$531,674	Oct-18	Sep-21
Alliance for Lupus Research	Calgary Site PI & Lupus Clinical Investigators Network (LuCIN)	<b>Clarke AE, Barr S</b>		\$80,000	\$160,000	Aug-16	open ended
CIHR	Evidence to action for Canadian and global mobile health (mHealth) communication to promote patient engagement in care: a rigorous implementation science approach	Lester R	V Cook, <b>M De Vera, J Fitzgerald, N Ford, J Johnston, A Kazi, M Murray, L Mwai, A Patel, M Schechter, S Skinner, P Spittal, M VanDerKop</b>	\$80,593	\$402,966	Jul-15	Jun-20
The Arthritis Society	Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis	<b>De Vera M</b>	<b>D Da Costa, J Puyat, J Esdaile, K Shojania, A Avina-Zubieta, A Howren,</b>	\$70,000	\$210,000	Oct-18	Sep-22
CIHR	PRECISION: Preventing Complications from Inflammatory Skin, Joint and Bowel Conditions	<b>Esdaile J</b>	<b>C Goldsmith, M De Vera, J Dutz, D Lacaille, LC Li</b>	\$484,538	\$2,422,690	Jul-14	Jun-19
CIHR	Dissemination of the Lupus Interactive Navigator - Measuring its uptake and impact on global health and self-care.	<b>Fortin P</b>	<b>D DaCosta, V Haroun</b>	\$100,000	\$200,000	Sep-16	Aug-18

CIHR - Foundation Scheme	Platelets and their microparticles: versatile players of inflammation	Boilard, E	<b>P Fortin</b>	\$286,979	\$1,434,894	Sep-14	Aug-19
CIHR - Operating Grant	Role of novel microparticle subtypes derived by platelets in SLE	Boilard, E	<b>P Fortin</b>	\$151,525	\$757,624	Mar-14	Feb-19
CIHR- Operating Grant	Role of autotoxin bound to platelet-derived microparticles to development of vascular damage in	Bourgoin S	E Boilard, <b>P Fortin</b>	\$157,781	\$788,904	Mar-15	Feb-20
CIORA	MyArthritisGuide for rheumatoid arthritis will improve patient's activation towards self-care	<b>Fortin P</b>	<b>D DaCosta</b> , M Rochon	\$57,500	\$115,000	Jul-18	Jun-18
CIHR	Impact of internet delivered cognitive behavioral therapy for insomnia in persons with systemic lupus	<b>Fortin P, Da Costa D, Savard J</b>	E Rahme	\$100,000	\$100,000	Mar-19	Feb-22
CIHR	Preventing adverse tissue reactions in total hip replacement, from mechanisms to new implant designs	Masri B, Wang R	M Cox, C Duncan, <b>D Garbuz, N Greidanus, T Ng, D Wang</b>	\$14,154	\$200,000	Apr-16	Mar-19
CIHR	A population-based analysis of multi-disciplinary rheumatology nursing care for people with complex rheumatic diseases.	<b>Harrison M</b>	<b>K Shojania</b> , M Law, K McGrail, <b>M De Vera, JA Avina-Zubieta</b> , R Sawatzky, <b>C Koehn</b> , J Kur, H Davidson	\$90,465.67	\$271,397	Jul-16	Jun-19
CIHR	Bridging the Evidence Gap: Understanding Patient and Physician Choices for Treatment in Early Rheumatoid Arthritis	<b>Hazlewood G</b>	<b>C Barnabe, D Marshall, L Li, N Bansback</b>	\$86,000	\$258,000	Oct-15	Sep-18

CIHR	A pragmatic registry-based randomized trial of drug tapering in rheumatoid arthritis	<b>Hazlewood G</b> , Bykerk V	<b>N Bansback</b> , R Deardon, L Proulx, G. Tomlinson, <b>C Barber</b> , E Keystone, D Richards, P Tugwell, <b>S Bartlett</b> , <b>D Marshall</b> , O Schier, G Boire, J Pope, C Thorne	\$159,694	\$638,776	Apr-18	Mar-21
CIHR	Hydroxychloroquine in systemic lupus	<b>Hazlewood G</b> , Bernatsky S	<b>Abrahamowicz M</b> , <b>Bartlett S</b> , <b>Clarke A</b> , <b>Fortin P</b> , Hanly J, <b>Li LC</b> , Peschken C, Vinet E	\$68,468	\$342,340	Apr-18	Mar-23
CIHR	Shoe insoles designed to target foot and knee symptoms in people with knee osteoarthritis: A randomized controlled study	<b>Hunt MA</b>		\$100,000	\$100,000	Mar-18	Feb-19
CIHR	Canadian MSK Rehab Research Network	Astephen Wilson JL, Birmingham T, Lyddiatt A, Macdermid J, Robinovitch S, Roy JS	M Ashe, D Beaton, L Beaupre, M Begon, L Bouyer, L Carlesso, M Choiniere, J Cote, N Dahan-Oliel, K Deluzio, F Desmeules, C Dionne, CA Emery, F Feldman, <b>MA Hunt</b> , <b>DA Marshall</b> et al	\$14,204.67	\$366,667	Sep-16	Aug-19
CIHR	Development of a new life expectancy and quality of life prediction model	<b>Kopec J</b>	<b>J Esdaile</b> , <b>LC Li</b> , <b>L Feehan</b> , <b>H Xie</b>	\$100,000	\$200,000	Oct-17	Sep-19
CIHR	Development and validation of Canadian health literacy measurement tool for chronic disease management.	Fitzgerald M, <b>Kopec JA</b>	I Rootman, SD Aaron, C Bergeron, LP Boulet, J Bourbeau, R Goldstein, S Gupta et al	\$160,601	\$803,004	Jul-15	Jun-20

CIORA	Understanding the barriers to self-management support for underserved populations living with arthritis and co-morbidities and developing patient-derived tools for healthcare policy and practice	<b>Lacaille D,</b> Mills S	S Koehn, GP Flores, N Clark, <b>C Koehn</b> , M Fong, A Louie	\$58,450	\$116,900	Oct-16	Sep-18
The Arthritis Society	Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis	<b>Lacaille D</b>	O Tseng, <b>C Barber</b> , <b>L Li</b> , <b>H Xie</b> , <b>JA Aviña-Zubieta</b> , <b>J Esdaile</b>	\$120,000	\$360,000	Sep-19	Aug-19
CIHR	Canadian network for advanced interdisciplinary methods for prospective studies of drug safety and effectiveness	<b>Abrahamowicz M</b>	<b>D Lacaille</b> , A Berard, S Bernatsky, C Hohl, L Levesque, A Levy, Y Moride, L Pilote, L Bessette, L Blais, G Boire, C Bombardier, D Buckeridge, S Cadarette, R Capek, <b>P Fortin</b> et al.	\$250,000	\$1,250,000	Sep-14	Aug-19
CIHR	New statistical methods for cohort studies of adverse effects of medications	<b>Abrahamowicz M</b>	Bernatsky S, Blais L, Brophy J, Buckeridge D, Bérard A, Capek R, <b>De Vera M</b> , Dixon W, Durand M, <b>Fortin P</b> , Klein M, <b>Lacaille D</b> , Moodie E, Moura C, Pilote L	\$55,724.60	\$278,623	Jul-16	Jun-21
The Arthritis Society	Empowering active self-management of arthritis: Raising the bar with OPERAS (an On-demand Program to Empower Active Self-management)	<b>Li LC</b>	T Liu-Ambrose, <b>C Backman</b> , C Shaw, <b>J Esdaile</b> , K Miller, R Petrella, L <b>Feehan</b> , <b>C Koehn</b> , <b>C Goldsmith</b> , P Adam	\$120,000	\$360,000	Oct-16	Sep-19



CIHR	An app-based intervention to empower self-management for people with rheumatoid arthritis	<b>Li LC, Lacaille D</b>	<b>C Backman, JM Esdaile, LM Feehan, H Xie, K Miller, C Shaw</b> Patient Partners: <b>C Koehn, K English</b> Collaborator: P Adam Tech Partner: Tactica Interactive	\$100,000	\$200,000	Sep-17	Aug-19
CIHR	SPOR Evidence Alliance	Tricco A, Straus S, Abou-Setta AM, Barker K, Clement F, Clifford TJ, Colquhoun H, Curran J, Godfrey C, Isaranuwatchai W, LeBlanc A, <b>Li LC</b> , Moffitt P, Moher D,	<b>Barnabe C</b> , Graham I, Ivers N, Klassen T, Legare F, Mitton C, Morin S, Scott S, Sibely K, Snelgrove-Clarke E, Squires J, plus > 100 investigators	\$999,378	\$4,996,890	Jul-17	Jun-22
CIORA	Power to the Patients: Reshaping Knee Osteoarthritis Diagnosis and Secondary Prevention with E-Health	<b>Li LC, Esdaile J</b>	<b>J Cibere</b> , G Hawker, <b>H Xie, C Koehn</b> , A Fajardo	\$57,500	\$115,000	Jul-18	Jun-19
CIHR	Transforming the practices of KT: Embedding Gender	Straus S, Moore J	A Chambers, L Giangregorio, A Giguere, I Graham, J Hamid, J Holroyd Leduc, C Kelly, <b>LC Li</b> , J Presseau, P Rochom et al	\$150,000	\$450,000	May-17	Mar-20

MSFHR	Implementing an evidence-based exercise program to reduce falls in community-dwelling seniors	<b>Li LC</b>	T Liu-Ambrose, S Murphy, F Feldman, M Oakey, J Davis, <b>J Ma, C Koehn</b> , L Dian, D Jehu, <b>H Xie</b>	\$10,000	\$10,000	Sep-18	Feb-19
CIHR	Towards better surgical outcomes through improved decision making about appropriateness for total knee arthroplasty in patients with knee osteoarthritis	<b>Marshall DA</b> , Hawker G	E Bohm, M Dunbar, P Faris, <b>A Jones</b> , T Noseworthy, B Ravi, L Woodhouse	\$208,848	\$1,044,241	Apr-14	Mar-19
CIORA	Measuring geographic variation in access to care for rheumatoid arthritis patients and related outcomes: A patient-centred approach	<b>Marshall DA</b> , <b>Barber CE</b>	S Bertazzon, A Patel, D Mosher, J Homik, S Katz, M Nasr	\$59,000	\$118,000	Aug-16	Jul-18
Alberta Innovates; APhi Development Grant	Alberta Precision Health Initiative for Arthritis and Complex Immune Diseases	<b>Marshall DA</b>	( <b>Kopec JA</b> , Member).	\$212,667	\$319,000	Jul-17	Dec-18
CIHR	UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	<b>Benseler S</b> , Swart J, Wulffraat N, Yeung R	C Bombardier, J Cafazzo, N Eijkelkamp, A Goldenberg, J Guzman, M Ijzerman, <b>DA Marshall</b> et al	\$8,553.40	\$1,023,753	Feb-17	Jan-22
The Vancouver Foundation	Early Arthritis Triage Strategy.	<b>Shojania K</b>		\$75,000	\$75,000	Apr-18	Mar-19
Natural Sciences & Engineering Research Council (NSERC)	Statistical Methods for bias controlling in the analysis of rich data	<b>Xie, H</b>		\$15,000.00	\$75,000	Apr-18	Mar-23

<b>SCIENTIST FUNDING - Salary Grants</b>					
<b>Peer Review</b>					
<b>Funding Agency</b>	<b>Title</b>	<b>Faculty</b>	<b>Start/End Date</b>	<b>Annual Amount</b>	<b>Total Awarded</b>
MSFHR	Career Investigator Award - Reducing the burden and gaps in care for patients with systemic autoimmune rheumatic diseases (ReGaIN SARDs)	<b>Avina A</b>	Jul 14 - Jun 19	\$90,000	\$450,000
CIHR	New Investigator Award - Arthritis care for Indigenous populations	<b>Barnabe C</b>	Jul 14 - Jul 19	\$60,000	\$300,000
CIHR	Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2)	<b>Barnabe C</b>	Oct 19 - Sep 24	\$100,000	\$500,000
CIHR	New Investigator Award - Can patient-centred care improve outcomes and save costs?	<b>Bansback N</b>	Jul 14 - Jul 19	\$60,000	\$300,000
Arthritis Alliance of Canada	Knowledge Translation Science/Research Award	<b>Bansback N</b>	Oct-18	\$750	\$750
MSFHR	Career Investigator award - Pharmacoepidemiologic and pharmaceutical outcomes research to improve medication use, adherence, and outcomes in patients with arthritis	<b>De Vera M</b>	Jul 14 - Jun 19	\$90,000	\$450,000
CIHR	Canada Research Chair in Medication Adherence, Utilization, and Outcomes (Scientist)	<b>De Vera M</b>	Apr 17 - Mar 22	\$100,000	\$500,000
CIHR	Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal	<b>P Fortin</b>	Apr19 - Mar 26	\$200,000	\$1,400,000

MSFHR	Scholar Award - Incentivizing the delivery of sustainable care of chronic diseases in Canada: case studies in musculoskeletal disease	<b>Harrison M</b>	Jul 17 - Jun 22	\$90,000	\$450,000
CIHR	New Investigator Salary Award - Bridging the gap between research evidence and patient-centered treatment approaches for chronic immune-mediated diseases	<b>Hazlewood G</b>	Jul 16 - Jun 21	\$60,000	\$300,000
TAS	New Investigator Salary Award - Impacts of integrating the patients' voice into the process of treatment selection for rheumatoid arthritis	<b>Hazlewood G</b>	Aug 16 - Jul 19	\$60,000	\$180,000
Canadian Rheumatology Association	Emerging Investigator Award	<b>Hazlewood G</b>	Feb-19	\$2,500	\$2,500
MSFHR	Career Clinical Scholar	<b>Hunt M</b>	Jul-12 - Jul-20	\$79,375	\$635,000
CIHR	New Investigator Award - Non-invasive treatments to improve disease symptoms and cartilage health for knee osteoarthritis	<b>Hunt M</b>	Jul-14 - Jul-19	\$60,000	\$300,000
Canadian Rheumatology Association	Distinguished Investigator Award	<b>Lacaille D</b>	Feb-19	\$2,500	\$2,500
MSFHR	Career Investigator Award	<b>Li L</b>	Sep-11 - Aug-19	\$79,375	\$635,000
Canada Research Chair	Canada Research Chair in Patient-Oriented Knowledge Translation	<b>Li L</b>	Jan-14 - Dec-19	\$100,000	\$500,000
Government of Canada	Canada Research Chair in Systemic Autoimmune Rheumatic Diseases	<b>Fortin P</b>	Apr-12 - Mar-19	\$200,000	\$1,400,000
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	<b>Marshall D</b>	Jul-12 - Jun-17		

Non Peer Review					
BC Lupus Society	Scholar Award	<b>Avina A</b>	Jul-10 - Jun-19	\$50,000	\$350,000
UBC	Mary Pack Chair	<b>Lacaille D</b>	Sep-11 -	\$164,759	\$823,799
UBC	Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences	<b>Li L</b>	Jul-11 -	\$94,333	\$283,000
SFU	Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease	<b>Xie H</b>	Sep-15 - Aug-20	\$172,000	\$4,000,000

TRAINEE AWARDS						
Funding Agency	Title	Trainee	Supervisor	Start/End Date	Annual Amount	Total Awarded
AAC	Arthritis Alliance of Canada Master's Student Award	<b>Brunet S</b>	<b>C Barnabe</b>	1-Oct-18	\$750	\$750
CIHR	Postdoctoral Fellowship - The effects of running on knee cartilage measures in people with and without knee osteoarthritis	<b>Esculier JF</b>	<b>M Hunt</b>	Jul 16 - Jun 19	\$55,000	\$165,000
MSFHR	Postdoctoral Fellowship Award - Development and validation of the Patient Engagement In Research Scale (PEIRS)	<b>Hamilton C</b>	<b>L Li</b>	Jul 16 - Jun 19	\$41,500	\$124,500
CIHR	Postdoctoral Fellowship Award - Developing and Testing of the Patient Engagement in Research Scale (PEIRS)	<b>Hamilton C</b>	<b>L Li</b>	Sep 18 - Dec 18	\$45,000	\$60,000
CIHR	Health System Impact Fellowship - Patient/Public Engagement Measurement and Evaluation Project (PEMEP) within the British Columbia Ministry of Health's Patients as Partners Initiative	<b>Hamilton C</b>	<b>L Li</b>	Sep 18 - Aug 20	\$77,500	\$155,000

CIHR - TAS	Building a foundation for an economic business case for models of care for patients with Inflammatory Arthritis in Canada (Supervisors: D Marshall, D Mosher)	<b>Lopatina E</b>	<b>Marshall D</b>	Sep 18 - Aug 19	\$35,000	\$35,000
AAC	Arthritis Alliance of Canada PhD Student Award	<b>Lopatina E</b>	<b>Marshall D</b>	Oct-18	\$750	\$750
Arthritis Health Professions Association (Ontario)	The health promoting potential of social and creative activities: an exploratory study of adults with and without inflammatory arthritis	<b>To-Miles F</b>	<b>C Backman</b>	Mar-19	\$5,000	\$5,000
CIHR	CIHR Allied Health Professionals Fellowship award -Safety of biologics use during pregnancy: a population-based study of women and infants.	<b>Tsao N</b>	<b>M De Vera</b>	May 17 - Apr 19	\$50,000	\$100,000
CIHR	CIHR Postdoctoral Award - Safety and Effectiveness of Anti-diabetic Drugs in Pregestational Diabetes	<b>Tsao N</b>	<b>M De Vera</b>	Sep 18 - Aug 21	\$60,000	\$180,000

## Appendix II

### PUBLICATIONS

1. Abderrazak A, El Azreq MA, Naci D, **Fortin PR**, Aoudjit F. Alpha2beta1 Integrin (VLA-2) protects activated human effector T cells from methotrexate-induced apoptosis. *Front Immunol*. 2018 Oct 15;9:2269.
2. Adam S, Birch PH, Coe RR, **Bansback N**, Jones AL, Connolly MB, Demos MK, Toyota EB, Farrer MJ, Friedman JM. Assessing an interactive online tool to support parents' genomic testing decisions. *J Genet Couns*. 2018 Jul 23. doi: 10.1007/s10897-018-0281-1. [Epub ahead of print].
3. Agrawal Y, Smith RM, **Garbuz DS**, Masri BA. Opioids in arthroplasty: mind the gap between North America and the rest of the world. *J Bone Joint Surg Am*. 2018 Dec 19;100(24):2162-2171.
4. Amlani A, **Choi M**, Tarnopolsky M, Brady L, **Clarke AE**, Garcia-De La Torre I, Mahler M, Schmeling H, **Barber CEH**, Jung M, Fritzler MJ. Anti-NT5c1A Autoantibodies as biomarkers in inclusion body byositis. *Front Immunol*. 2019 Apr 9;10:745.
5. **Aviña-Zubieta JA, Chan J, De Vera MA, Sayre EC, Choi HK, Esdaile JM**. Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study. *Ann Rheum Dis*. 2019 Apr;78(4):480-485.
6. **Atiquzzaman M**, Karim ME, **Kopec J**, Wong H, **Anis AH**. Role of non-steroidal anti-inflammatory drugs (NSAIDs) in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. *Arthritis Rheumatol*. 2019 Aug 6. doi: 10.1002/art.41027. [Epub ahead of print] .
7. **Bansback N, Trenaman L**, MacDonald KV, Hawker G, Johnson JA, Stacey D, **Marshall DA**. An individualized patient-reported outcome measure (PROM) based patient decision aid and surgeon report for patients considering total knee arthroplasty: protocol for a pragmatic randomized controlled trial. *BMC Musculoskelet Disord*. 2019 Feb 23;20(1):89.
8. Barbacki A, Petri M, **Avina-Zubieta JA**, Alarcón GS, Bernatsky S. Fatigue measurements in systemic lupus erythematosus. *J Rheumatol*. 2019 Feb 1. pii: jrheum.180831. doi: 10.3899/jrheum.180831. [Epub ahead of print].
9. Barber T, Sharif B, Teare S, Miller J, Shewchuk B, Green LA, Marlett N, **Cibere J**, Mrklas K, Wasylak T, **Li LC**, Campbell-Scherer D, **Marshall DA**. A qualitative study to elicit patients' and primary care physicians' perspectives on the use of a self-management mobile health application for knee osteoarthritis. *BMJ Open*. 2019 Feb 1;9(1):e024016.
10. **Barber CEH**, Sandhu N, Rankin JA, MacMullan P, **Marshall DA**, **Barnabe C**, **Hazlewood GS**, Emrick A, Stevenson M, Then KL, Benseler S, Twilt M, Mosher D. Rheum4U: development and testing of a web-based tool for improving the quality of care for patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2019 May-Jun;37(3):385-392.

11. Barclay R, Webber S, Ripat J, Grant T, **Jones CA**, Lix LM, Mayo N, van Ineveld C, Salbach NM. Safety and feasibility of an interactive workshop and facilitated outdoor walking group compared to a workshop alone in increasing outdoor walking activity among older adults: a pilot randomized controlled trial. *Pilot Feasibility Stud.* 2018 Nov 29;4:179.
12. **Barnabe C**, Zheng Y, Ohinmaa A, Crane L, White T, Hemmelgarn B, Kaplan GG, Martin L, Maksymowych WP. Effectiveness, complications, and costs of rheumatoid arthritis treatment with biologics in Alberta: experience of Indigenous and non-Indigenous patients. 2018;45(10)1344-1352.
13. Beaupre LA, Magaziner JS, **Jones CA**, Jhangri GS, Johnston DWC, Wilson DM, Majumdar SR. Rehabilitation after hip fracture for nursing home residents: a controlled feasibility trial. *J Gerontol A Biol Sci Med Sci.* 2019 Feb 9. doi: 10.1093/gerona/glz031. [Epub ahead of print].
14. Becker Y, Marcoux G, Allaey I, Julien A-S, Loignon R-C, Benk-Fortin H, Rollet-Labelle E, Rauch J, **Fortin PR**, Boilard E. Autoantibodies in systemic lupus erythematosus target mitochondrial RNA. *Front. Immunol.* 2019-May 10; 10:1026. doi: 10.3389/fimmu.2019.01026.
15. Becker Y, Loignon RC, Julien AS, Marcoux G, Allaey I, Lévesque T, Rollet-Labelle E, Benk-Fortin H, Cloutier N, Melki I, Eder L, Wagner É, Pelletier M, Hajj HE, Tremblay MÉ, Belleannée C, Hébert MJ, Dieudé M, Rauch J, **Fortin PR**, Boilard E. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. *Sci Rep.* 2019 Mar 14;9(1):4530.
16. Brooks L, Ta KN, **Townsend AF**, **Backman CL**. "I just love it": Avid knitters describe health and well-being through occupation. *Can J Occup Ther.* 2019 Apr;86(2):114-124.
17. Campbell EJ, **Clarke AE**, Ramsey-Goldman R. Systemic lupus erythematosus: a case-based presentation of renal, neurologic, and hematologic emergencies. *Expert Rev Clin Immunol.* 2018 Oct;14(10):803-816.
18. **Charlton JM**, Xia H, Shull PB, **Hunt MA**. Validity and reliability of a shoe-embedded sensor module for measuring foot progression angle during over-ground walking. *J Biomech.* 2019 May 24;89:123-127.
19. **Charlton JM**, Hatfield GL, Guenette JA, **Hunt MA**. Ankle joint and rearfoot biomechanics during toe-in and toe-out walking in people with medial compartment knee osteoarthritis. *Journal of the American Academy of Physical Medicine and Rehabilitation.* 2019 May;11(5):503-511.
20. **Charlton JM**, Hatfield GL, Guenette JA, **Hunt MA**. Toe-in and toe-out walking require different lower limb neuromuscular patterns in people with knee osteoarthritis. *J Biomech.* 2018 Jul 25;76:112-118.
21. Chen-Xu M, Yokose C, **Rai SK**, Pillinger MH, **Choi HK**. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey 2007-2016. *Arthritis Rheumatol.* 2019 Jun;71(6):991-999.



22. **Chin C, Sayre EC**, Guerhazi A, Nicolaou S, **Esdaile JM, Kopec J**, Thorne A, Singer J, Wong H, **Cibere J**. Quadriceps weakness and the risk of knee cartilage loss on magnetic resonance imaging in a population-based cohort with knee pain. *J Rheumatol*. 2019 Feb;46(2):198-203. <https://doi.org/10.3899/jrheum>.
23. **Choi MY, Clarke AE**, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, **Fortin PR**, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. *Arthritis Care Res (Hoboken)*. 2019 Jul;71(7):893-902.
24. **Choi MY, Barnabe C, Barber C**, Bykerk V, Pope V, **Hazlewood GS**. Pragmatism of randomized controlled trials of biologic treatment with methotrexate in rheumatoid arthritis: a systematic review. *Arthritis Care & Research*, May 2019;71(5):620-628.
25. **Cibere J**, Guerhazi A, Nicolaou S, **Esdaile JM**, Thorne A, Singer J, Wong H, **Kopec JA, Sayre EC**. Association of knee effusion detected by physical examination with bone marrow lesions: cross-sectional and longitudinal analyses of a population-based cohort. *Arthritis Care Res (Hoboken)*. 2019 Jan;71(1):39-45.
26. Collins K, Sharif B, Sanmartin C, Herzog W, Chin R, **Marshall DA**. Association of metabolic markers with self-reported osteoarthritis among middle-aged BMI-defined non-obese individuals: a cross-sectional study. *BMC Obesity* 2018;5:23.
27. Coward S, Clement F, Benchimol E, Bernstein C, **Avina-Zubieta JA**, Bitton A, Carroll M, **Hazlewood G**, Jacobsen K, Jelinski S, Deardon R, Jones J, Kuenzig D et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. *Gastroenterology*. 2019 April;156(5)1345-1353.
28. Crown W, Buyukkaramikli N, Sir M, Thokala P, Morton A, **Marshall DA**, Tosh J, Ijzerman M, Padula W, Pasupathy K. Application of constrained optimization methods in health services research: Report 2 of the ISPOR Optimization Methods Good Practices Task Force. *Value in Health*. 2018; 21(9):1019-1028.
29. Dalbeth N, Frampton C, Fung M, Baumgartner S, Nicolaou S, **Choi HK**. Concurrent validity of provisional remission criteria for gout: a dual-energy CT study. *Arthritis Res Ther*. 2019 Jun 21;21(1):150.
30. de Jesús GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, **Fortin PR**, APS ACTION et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. *International Journal of Obstetrics and Gynaecology*. 2019 Apr;126(5):656-661.

31. **De Vera MA**, Baldwin C, **Tsao N**, **Howren A**, **Hazlewood GS**, **Rebic N**, Ensworth S. Management of inflammatory arthritis in pregnancy: a national cross-sectional survey of Canadian rheumatologists. *BMC Rheumatol*. 2019 May 17;3:18. doi: 10.1186/s41927-019-0065-8. eCollection 2019.
32. Diamond OJ, Konan S, **Greidanus NV**, **Garbuz DS**, Duncan CP, Masri BS. An early report of the use of a modular dual mobility articulation in revision acetabular reconstruction. *J Arthroplasty*. 2018 Sep;33(9):2961-2966.
33. Durand C, Eldoma M, **Marshall DA**, **Bansback N**, **Hazlewood GS**. Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: a systematic review. *J Rheumatol*. April 15, 2019. doi: 10.3899/jrheum.181165.
34. El-Husseiny M, Masri B, Duncan C, **Garbuz DS**. Long-term results of tripolar constrained total hip arthroplasty in revision hip arthroplasty: a minimum follow-up of ten years. *Bone Joint J*. 2019 Jun;101-B(6\_Supple\_B):123-126.
35. **Esculier JF**, Barton C, Whiteley R, Napier C. Involving clinicians in sports medicine and physiotherapy research: 'design thinking' to help bridge gaps between practice and evidence. *Br J Sports Med*. 2018 Dec;52(24):1550-1551
36. **Esculier JF**, Krowchuk NM, **Li LC**, Taunton Jack E, **Hunt MA**. What are the perceptions about running and knee joint health among the public and healthcare practitioners in Canada? *PLOS One*. 2018 Oct 1;13(10):e0204872. <https://doi.org/10.1371/journal.pone.0204872>.
37. Essers I, Hilgsmann M, Kiltz U, **Bansback N**, Braun J, van der Heijde D, Boonen A. Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. *Rheumatic & Musculoskeletal Diseases Open*. 2019 May 21;5(1):e000872.
38. Etminan M, Sodhi M, Samii A, Carleton B, Kezouh A, **Aviña-Zubieta JA**. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. *Semin Arthritis Rheum*. 2019 Jun;48(6):1083-1086.
39. **Feehan LM**, **Geldman J**, **Sayre EC**, **Park C**, Ezzat AM, Yoo JY, **Hamilton CB**, **Li LC**. Accuracy of Fitbit devices: systematic review and narrative syntheses of quantitative data. *JMIR Mhealth Uhealth*. 2018 Aug 9;6(8):e10527.
40. Ferdowsi N, Huq M, Stevens W, **Hudson M**, Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group (incl **Fortin PR**) et al. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. *Ann Rheum Dis*. 2019 Jun;78(6):807-816.
41. Fitzcharles MA, Zahedi Niaki O, Hauser W, **Hazlewood G**. The Canadian Rheumatology Association Position Statement: A pragmatic approach for medical cannabis and patients with rheumatic diseases. *J Rheumatol*. 2019 May;46(5):532-538.

42. Frolkis AD, V, **Barnabe C**, Patten SB, Kaplan GG et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. *Gut*. 2018 Oct 18. pii: gutjnl-2018-317182. doi: 10.1136/gutjnl-2018-317182. [Epub ahead of print].
43. Gallina A, Wakeling JM, Hodges PW, **Hunt MA**, Garland SJ. Regional vastus medialis and vastus lateralis activation in females with patellofemoral pain. *Med Sci Sports Exerc*. 2019 Mar;51(3):411-420.
44. Global Burden of Disease 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, Abajobir AA, Abate KH, **Kopec JA** et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. *N Engl J Med*. 2018 Dec 20;379(25):2429-2437.
45. Global Burden of Disease 2017 SDG Collaborators (**Kopec JA**, Member). Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):2091-2138.
46. Global Burden of Disease 2017 Population and Fertility Collaborators Global Burden of Disease (**Kopec JA**, Member). Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1995-2051.
47. Global Burden of Disease 2017 Risk Factor Collaborators (**Kopec JA**, Member). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1923-1994.
48. Global Burden of Disease 2017 Disease and Injury Incidence and Prevalence Collaborators (**Kopec JA**, Member). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1789-1858.
49. Global Burden of Disease 2017 Causes of Death Collaborators (**Kopec JA**, Member). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1736-1788.
50. Global Burden of Disease 2017 Mortality Collaborators (**Kopec JA**, Member). Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1684-1735.

51. Global Burden of Disease 2017 DALYs and HALE Collaborators (**Kopec JA**, Member). Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1859-1922.
52. Gignac MAM, Irvin E, Cullen K, Van Eerd D, Beaton DE, Mahood Q, McLeod C, **Backman CL**. Men and women's occupational activities and the risk of developing osteoarthritis of the knee, hip or hands: a systematic review and recommendations for future research. *Arthritis Care Res (Hoboken)*. 2019 Feb 14. doi: 10.1002/acr.23855. [Epub ahead of print].
53. Global Burden of Disease 2016 Greece Collaborators, (**Kopec JA**, Member). The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of the Global Burden of Disease Study 2016. *Lancet Public Health*. 2018 Aug;3(8):e395-e406.
54. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Brenner H, Cahuana-Hurtado L, Castañeda-Orjuela CA, Catalá-López F, Choi JJ, and (**Kopec JA**, Member). et al. Global, Regional, and National Cancer Incidence, Mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. *JAMA Oncol*. 2018 Nov 1;4(11):1553-1568.
55. Gong B, **Shojania K**, Khosa F, Nicolaou S. Referral patterns for dual-energy computed tomography in diagnosis and management of gout: ten-year experience at a Canadian institution. *Can Assoc Radiol J*. 2018 Nov;69(4):430-436.
56. Greenwood-Lee J, Jewett L, Woodhouse L, **Marshall DA**. A categorisation of problems and solutions to improve patient referrals from primary to specialty care. *BMC Health Serv Res*. 2018 Dec 20;18(1):986.
57. **Guo Y**, Zhang H, Qian H, Wilson DR, Wong H, **Barber M**, Forster BB, **Esdaille J**, **Cibere J**. Association of femoroacetabular impingement and delayed gadolinium-enhanced magnetic resonance imaging of cartilage: a population-based study. *Arthritis Care Res (Hoboken)*. 2018 Aug;70(8):1160-1168.
58. **Hamilton CB**, **Hoens AM**, **McQuitty S**, **McKinnon AM**, **English K**, **Backman CL**, **Azimi T**, **Khodarahmi N**, **Li LC**. Development and pre-testing of the Patient Engagement In Research Scale (PEIRS) to assess the quality of engagement from a patient perspective. *PLoS One*. 2018 Nov 1;13(11):e0206588.
59. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR** et al. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Rheumatol*. 2019 Feb; 71(2):281-289.

60. Harel D, Mills SD, Kwakkenbos L, Carrier ME, Nielsen K, Portales A, **Bartlett SJ**, Malcarne VL, Thombs BD, **Fortin PR**; and the SPIN Investigators. Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. *BMJ Open*. 2019 Feb 22;9(2):e024010.
61. **Harrison M**, Spooner L, **Bansback N**, Milbers K, **Koehn C**, **Shojania K**, Finckh A, **Hudson M**. Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individuals. *PLoS One*. 2019 Apr 25;14(4):e0216075.
62. Herman A, Masri BA, Duncan CP, **Greidanus NV**, **Garbuz DS**. Multivariate analysis of risk factors for re-dislocation after revision for dislocation after total hip arthroplasty. *Hip Int*. 2019 Mar 19:1120700019831628. [Epub ahead of print].
63. Herman A, Albers A, **Garbuz DS**, Duncan CP, Masri BA. Classic markers for infection perform poorly in predicting residual infection prior to reimplantation. *Orthopedics*. 2019 Jan 1;42(1):34-40.
64. Hiligsmann M, Rademacher S, Kaal KJ, **Bansback N**, **Harrison M**. The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. *Semin Arthritis Rheum*. 2018 Dec;48(3):357-366.
65. Huang K, **Shojania K**, Chapman K, Amiri N, Dehghan N, Mezei M. Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: a case series and literature review. *Semin Arth Rheum*. 2019 Feb;48(4):745-751.
66. **Hunt MA**, **Charlton JM**, Krowchuk NM, Tse CTF, Hatfield GL. Clinical and biomechanical changes following a 4-month toe-out gait modification program for people with medial knee osteoarthritis: a randomized controlled trial. *Osteoarthritis Cartilage*. 2018 Jul;26(7):903-911.
67. Iragorri N, **Hazlewood G**, Manns B, Danthurebandara V, Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. *Rheumatology (Oxford)*. 2019 Apr 1;58(4):692-707.
68. Jin X, Al Sayah F, Ohinmaa A, **Marshall DA**, Smith C, Johnson JA. *Corr Insights®*. The EQ-5D-5L is superior to the -3L Version in measuring health-related quality of life in patients awaiting total hip arthroplasty or total knee arthroplasty. *Clin Orthop Relat Res*. 2019 2019 Jul;477(7):1645-1647.
69. Johnson RJ, **Choi HK**, Yeo AE, Lipsky PE. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. *Hypertension*. 2019 Jul;74(1):95-101.
70. Jordan DM, **Choi HK**, Verbanck M, Topless R, Won HH, Nadkarni G, Merriman TR, Do R. No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study. *PLoS Med*. 2019 Jan 15;16(1):e1002725.
71. Jorge A, Wallace ZS, **Lu N**, Zhang Y, **Choi HK**. Renal transplantation and survival among patients with lupus nephritis: a cohort study. *Ann Intern Med*. 2019 Jan 22. doi: 10.7326/M18-1570. [Epub ahead of print].

72. Jorge AM, Melles RB, Zhang Y, **Lu N, Rai SK**, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, **Esdaille JM, Clarke AE**, Urowitz MB, Askanase A, Aranow C, Petri M, **Choi H**. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. *Arthritis Res Ther*. 2018 Jul 5;20(1):133.
73. Jorge A, Wallace ZS, Lu N, Zhang Y, **Choi HK**. Renal transplantation and survival among patients with lupus nephritis: a cohort study. *Ann Intern Med*. 2019 Jan 22. doi: 10.7326/M18-1570. [Epub ahead of print].
74. Jorge A, Ung C, Young LH, Melles RB, **Choi HK**. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. *Nat Rev Rheumatol*. 2018 Dec;14(12):693-703.
75. Jorge A, Wallace ZS, Zhang Y, **Lu N**, Costenbader KH, **Choi HK**. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. *Arthritis Rheumatol*. 2019 Mar;71(3):403-410.
76. Jorge AM, **Lu N**, Keller SF, **Rai SK**, Zhang Y, **Choi HK**. The effect of statin use on mortality in systemic autoimmune rheumatic diseases. *J Rheumatol*. 2018 Dec;45(12):1689-1695.
77. Kang EH, **Choi HK**, Shin A, Lee YJ, Lee EB, Song YW, Kim SC. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nationwide cohort study. *Rheumatology (Oxford)*. 2019 May 16. pii: kez189. doi: 10.1093/rheumatology/kez189. [Epub ahead of print].
78. Keeling S, **Aviña-Zubieta JA**, Barr SG, Bernatsky S, Bourre-Tessier J, **Clarke AE, Dutz J**, Ensworth S, **Fortin PF**, Gladman D, Hanly J, Hiraki L, Hussein S, Legault K, Levy D, Peschken C, Pineau C, Pope J, Urowitz M, Vinet E, et al. Canadian Rheumatology Association (CRA) recommendations for the assessment and monitoring of systemic lupus erythematosus in Canada. *J Rheumatol*. 2018 Oct;45(10):1426-1439.
79. Keeling S, Bissonauth A, Bernatsky S, Vandermeer B, **Fortin PR**, Gladman D, Peschken C, Urowitz MB. Practice variations in the diagnosis, monitoring, and treatment of systemic lupus erythematosus in Canada. *J Rheumatol*. 2018;45(10):1440-1447.
80. Keeling SO, Alabdurubalnabi Z, **Avina-Zubieta A**, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, **Clarke A**, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, **Fortin PR** et al. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus. *J Rheumatol*. 2018 Oct;45(10):1426-1439.
81. Kim H, Levy DM, Silverman ED, Hitchon C, Bernatsky S, Pineau C, Smith CD, Tucker L, Petty R, Arbillaga H, Zummer M, **Hudson M, Fortin P** et al. A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. *Rheumatology (Oxford)*. 2019 Feb 25. pii: kez006. doi: 10.1093/rheumatology/kez006. [Epub ahead of print].

82. **Kobsar D, Charlton JM, Hunt MA.** Individuals with knee osteoarthritis present increased gait pattern deviations as measured by a knee-specific gait deviation index. *Gait Posture*. 2019 May 29;72:82-88.
83. Konan S, Duncan CP, Masri BA, **Garbuz DS.** The cup-cage reconstruction for pelvic discontinuity has encouraging patient satisfaction and functional outcome at median 6-year follow-up. *Hip Int*. 2017 Sep 19;27(5):509-513.
84. **Kopec JA,** Qian H, **Cibere J,** Wong H, **Li LC, Barber M, Prlic H,** Zhang C, Ratzlaff C, Forster BB, **Esdaile JM** and the IMPAKT-HIP Study Team. Relationship between hip morphology and hip-related patient-reported outcomes in young and middle-aged individuals: a population-based study. *Arthritis Care Res (Hoboken)*. 2018 Oct 8. doi: 10.1002/acr.23774. [Epub ahead of print].
85. Kudaeva F, Speechley M, Klar N, Scheier O, **Bartlett S,** Bessette S, Bessette L, Boire G, **Hazlewood GS** et al, on behalf of Canadian Early Arthritis Cohort (CATCH) investigators. Association of Arthritis Onset with Influenza: analysis of the Canadian Early Inflammatory Arthritis Cohort. *ACR Open Rheumatology* March 2019;1(1):63-69.
86. Kuenzig M, **Barnabe C,** Seow CH, Eksteen B, Negron ME, Rezaie A, Panaccione R, Benchimol EI, Sadatsafavi M, **Aviña-Zubieta JA,** Kaplan GG. Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study. *Clin Epidemiol*. 2018 Jul 12;10:831-840.
87. Kulhawy-Wibe SC, Zell J, Michaud K, Yazdany J, Davis AM, Ehrlich-Jones L, Throne JC, Everix D, Cappelli LC, Suter LG, Limanni A, **Barber CEH.** A systematic review and appraisal of the cross-cultural validity of functional status assessments measures in rheumatoid arthritis. *Arthritis Care Res*. April 12, 2019. doi: 10.1002/acr.23904.
88. Kulhawy-Wibe S, King-Shier KM, **Barnabe C,** Manns BJ, Hemmelgarn BR, Campbell DJT. Exploring structural barriers to diabetes self-management in Alberta First Nations communities. *Diabetol Metab Syndr*. 2018 Dec 3;10:87.
89. Kurmis AP, Herman A, McIntyre AR, Masri BA, **Garbuz DS.** Pseudotumors and high-grade aseptic lymphocyte-dominated vasculitis-associated lesions around total knee replacements identified at aseptic revision surgery: findings of a large-scale histologic review. *J Arthroplasty*. 2019 May 17. pii: S0883-5403(19)30508-X. doi: 10.1016/j.arth.2019.05.025. [Epub ahead of print].
90. Ladouceur A, Bernatsky S, Ramsey-Goldman R, **Clarke AE.** Managing cancer risk in patients with systemic lupus erythematosus. *Expert Rev Clin Immunol*. 2018 Oct;14(10):793-802.
91. Lee J, Pineau CA, **Da Costa D, Clarke AE, Fortin PR,** Neville C, Neville A, Bernatsky S. Response to Middleton KR et als. Yoga and SLE. *Complement Ther Med*. 2019 Apr; 43:311. doi: 10.1016/j.ctim.2019.02.019. Epub 2019 Feb 28. PubMed PMID: 30935550.

92. **Leese J, Macdonald GG, Tran BC, Wong R, Backman CL, Townsend AF, Davis AM, Jones CA, Gromala D, Avina-Zubieta JA, Hoens, A, Li LC.** Using physical activity trackers in arthritis self-management: a qualitative study of patient and rehabilitation professional perspectives. *Arthritis Care Res*, 2019 Feb;71(2):227-236.
93. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE, Merrill JT, Ginzler EM, Fortin P** et al. Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus. *Arthritis Rheumatol*. 2019 August;71(8):1297-1307.
94. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE, Merrill JT, Ginzler EM, Fortin P** et al. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. *J Rheumatol*. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print].
95. Lewinson RT, Vallerand IA, LaMothe JM, Parsons LM, Frolkis AD, Lowerison MW, Patten SB, **Barnabe C.** Increasing rates of arthroplasty for psoriatic arthritis in the United Kingdom between 1995 and 2010. *Arthritis Care Res (Hoboken)*. 2018 Oct 24. doi: 10.1002/acr.23793. [Epub ahead of print].
96. Lin CY, **Loyola-Sanchez A, Hurd K, Ferucci ED, Crane L, Healy B, Barnabe C.** Characterization of Indigenous community engagement in arthritis studies conducted in Canada, United States of America, Australia and New Zealand. *Semin Arthritis Rheum*. 2019 Aug;49(1):145-155.
97. Ling D, Larry L, **Harrison M, Aslam AH, Bansback N.** Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. *J Comp Eff Res*. 2019 Jan;8(1):7-19.
98. **Lopatina E, Miller JL, Teare SR, Marlett NJ, Patel J, Barber CEH, Mosher DP, Wasylak T, Woodhouse LJ, Marshall DA.** The voice of patients in system redesign: a case study of redesigning a centralized system for intake of referrals from primary care to rheumatologists for patients with suspected rheumatoid arthritis. *Health Expect*. 2019 Jun;22(3):348-363.
99. **Loyola-Sanchez A, Hazlewood G, Crowshoe L, Linkert T, Hull PM, Marshall D, Barnabe C.** Qualitative study of treatment preferences for rheumatoid arthritis and pharmacotherapy acceptance: Indigenous patient perspectives. *Arthritis Care Res (Hoboken)*. 2019 Mar 1. doi: 10.1002/acr.23869. [Epub ahead of print].
100. Manske SL, Brunet SC, Finzel S, Stok KS, Conaghan PG, Boyd SK, **Barnabe C.** The SPECTRA Collaboration OMERACT Working Group: criterion validity of joint space outcomes with high resolution peripheral quantitative computed tomography. *J Rheumatol*. 2019 Jan 15. pii: jrheum.180870. doi: 10.3899/jrheum.180870. [Epub ahead of print].



101. **Marshall DA**, Liu X, Shahid R, Bertazzon S, Seidel JE, Patel AB, Nasr M, **Barber CEH**, McDonald T, Sharma R, Briggs T, Faris P, Waters N. Geographic variation in osteoarthritis prevalence in Alberta: a spatial analysis approach. *Applied Geography*. 2019; 103(2019):112-121.
102. **McCormick N, Hamilton CB, Koehn CL, English K**, Stordy A, **Li LC**. Canadians' views on the use of routinely collected data in health research: a patient-oriented cross-sectional survey. *CMAJ Open*. 2019;7(2):E203–9. <http://cmajopen.ca/content/7/2/E203.full>
103. McDonald EG, Bisdsonette L, Ensworth S, Dayan N, **Clarke AE**, Keeling S, Bernatsky S, Vinet E. Monitoring of systemic lupus erythematosus pregnancies: a systematic literature review. *J Rheumatol*. 2018;45(10):1477-1490.
104. McLane P, **Barnabe C**. Indigenous health research in emergency medicine. *Can J Emergency Med*. 2019 Jan;21(1):5-6.
105. Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, **Clarke AE**, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, **Fortin P** et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. *Rheumatology (Oxford)*. 2019 Jul 1;58(7):1259-1267.
106. Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, **Clarke AE**, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, **Fortin PR** et al. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. *Ann Rheum Dis*. 2019 Jul;78(7):1010-1012.
107. Michaels-Igbokwe C, Lee R, **Marshall DA**, Currie G. Economic evaluations of strategies to prevent sports and recreational injury among children and adolescents: a systematic review. *Inj Prev*. 2019 Aug;25(4):340-347.
108. Miller FA, Patton SJ, Dobrow M, **Marshall DA**, Berta W. Public involvement & Health research system governance: a qualitative study. *Health Research Policy & Systems* 2018;16(87).
109. Moura CS, Schieir O, Valois MF, Thorne C, **Barlett SJ**, Pope JE, Hitchon CA, Boire G, Haraoui B, **Hazlewood GS**, Keystone EC, Tin D, Bykerk VP, Bernatsky S, Canadian Early Arthritis Cohort (CATCH) Investigators. Treatment strategies in early rheumatoid arthritis methotrexate management: results from a prospective cohort. *Arthritis Care Research*, May 21, 2019. doi: 10.1002/acr.23927.
110. Munro S, Sou J, Zhang W, Mohammadi T, **Trenaman L**, Langlois S, **Anis AH**. Attitudes toward prenatal screening for chromosomal abnormalities: a focus group study. *Women Birth*. 2019 Aug;32(4):364-371.
111. Napier C, MacLean CL, Maurer J, Taunton JE, **Hunt MA**. Kinetic risk factors of running-related injuries in female recreational runners. *Scand J Med Sci Sports*. 2018 Oct;28(10):2164-2172.

112. Napier C, MacLean CL, Maurer J, Taunton JE, **Hunt MA**. Real-time biofeedback of performance to reduce braking forces associated with running-related injury: an exploratory study. *J Orthop Sports Phys Ther*. 2019 Mar;49(3):136-144.
113. Napier C, MacLean CL, Maurer J, Taunton JE, **Hunt MA**. Kinematic correlates of kinetic outcomes associated with running-related injury. *J Appl Biomech*. 2019 Apr 1;35(2):123-130.
114. Ostermann J, Brown DS, van Til JA, **Bansback N**, Légaré F, **Marshall DA**, Bewtra M. Support tools for preference-sensitive decisions in healthcare: where are we? Where do we go? How do we get there? *Patient*. 2019 Jun 29. doi: 10.1007/s40271-019-00372-z. [Epub ahead of print].
115. Oviedo-Joekes E, **Anis AH**, Guh D, Marsh DC, Palis H, Marchand K, Lock K, Schechter M, MacDonald S, Harrison S, Brissette S. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. *J Subst Abus*. 2019. 2019 (101):50-54.
116. Peláez-Ballestas I, Granados Y, Quintana R, **Loyola-Sánchez A** et al. Latin American Study Group of Rheumatic Diseases in Indigenous Peoples (GLADERPO). Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem. *Ann Rheum Dis*. 2018 Oct;77(10):1397-1404.
117. **Park JYE**, Li J, **Howren A**, **Tsao NW**, **De Vera M**. Mobile phone apps targeting medication adherence: quality assessment and content analysis of user reviews. *JMIR Mhealth Uhealth*. 2019 Jan 31;7(1):e11919.
118. Peschken CA, Wang Y, **Abrahamowicz M**, Pope J, Silverman E, Sayani A, Iczkowitz S, Ross J, Zummer M, Tucker L, Pineau C, Levy D, **Hudson M**, Hitchon CA, Huber AM, Smith CD, **Avina-Zubieta A**, Arbillaga H, Chédeville G, Wynant W, **Fortin PR**; CaNIOS 1000 Faces Investigators. Persistent disease activity remains an unmet need of lupus patients. *J Rheumatol*. 2019 Feb;46(2):166-175.
119. Phillips KA, Deverka PA, **Marshall DA**, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. *Value in Health*, September 2018; 21(9): 1033-1042.
120. Pollock CL, **Hunt MA**, Vieira TM, Gallina A, Ivanova TD, Garland SJ. Challenging standing balance reduces the asymmetry of motor control of postural sway poststroke. *Motor Control*. 2019 Jul 1;23(3):327-343.
121. Radin M, Sciascia S, Doruk E, Vittorio P, Tektonidou M, Ugarte A, Meroni P, Ji L, Belmont MH, Cohen H, Ramires de Jesus G, Branch WD, **Fortin PR** et al. (2019). The Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. *Semin Arthritis Rheum*. 2019 May 2. pii: S0049-0172(19)30090-3.

122. **Rai SK, Howren A, Wilcox ES, Townsend AF, Marra CA, Avina-Zubieta JA, De Vera MA.** Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus group activity. *Patient Prefer Adherence*. 5 October 2018;(12)2015—2025.
123. Regier DA, Weymann D, Buchanan J, **Marshall DA**, Wordsworth S. Valuation of health and non-health benefits from next generation sequencing: approaches, challenges, and solutions. *Value in Health*, September 2018; 21(9):1043-1047.
124. Richard N, **Hudson M**, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, **Fortin PR**; Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Baron M. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. *Rheumatology (Oxford)*. 2019 Apr 1;58(4):636-644.
125. Rizzardo S, **Bansback N**, Dragojlovic N, Douglas C, Li KH, Mitton C, **Marra C**, Blanis L, Lynd LD. Evaluating Canadians' values for drug coverage decision making. *Value Health*. 2019 Mar;22(3):362-369.
126. Schlesinger N, **Lu N, Choi HK.** Gout and the risk of incident erectile dysfunction: a body mass index-matched population-based study. *J Rheumatol*. 2018 Aug;45(8):1192-1197.
127. Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, **Fortin PR** et al. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. *Thromb Res*. 2019 Jan 18;175:32-36.
128. Slaughter SE, **Jones CA**, Eliasziw M, Ickert C, Estabrooks CA, Wagg AS. The changing landscape of continuing care in Alberta: staff and resident characteristics in supportive living and long-term care. *Healthc Policy*. 2018 Aug;14(1):44-56.
129. Spackman E, Clement F, Allan GM, Bell CM, Bjerre LM, Blackburn DF, Blais R, **Hazlewood G**, Klarenbach S, Nicolle LE, Persaud N, Alessi-Severini S, Tierney M, Wijeyesundera HC, Manns B. Developing key performance indicators for prescription medication systems. *PLoS One*. 2019 Jan 15;14(1):e0210794.
130. **Stewart M, Cibere J, Sayre EC, Kopec JA.** Efficacy of commonly prescribed analgesics in the management of osteoarthritis: a systematic review and meta-analysis. *Rheumatol Int*. 2018 Nov;38(11):1985-1997.
131. **Tan JA, Choi HK, Xie H, Sayre EC, Esdaile JM, Avina-Zubieta JA.** All-cause and cause-specific mortality in patients with granulomatosis with polyangiitis: a population-based study. *Arthritis Care Res (Hoboken)*. 2019 Jan;71(1):155-163.
132. Tanuseputro P, Arnason T, Hennessy D, Smith B, Bennett C, **Kopec J**, Pinto AD, Perez R, Tuna M, Manuel D. Simulation modeling to enhance population health intervention research for chronic disease prevention. *Can J Public Health*. 2019 Feb;110(1):52-57.

133. Targownik L, Benchimol E, Berntein C, Singh H, Lis L, Tennakoon A, Leung S, **Avina-Zubieta JA**, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen G, Pena-Sanchez JN. Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study. *Clinical Gastroenterology and Hepatology* 2019;17:1788–1798.
134. Toupin-April KT, Barton JL, Fraenkel L, Meara A, **Li LC**, Brooks P, de Wit M, Stacey D, Légaré F, Shea B, Lyddiatt A, Hofstetter C, Christensen R, Voshaar MS, Suarez and **Bartlett SJ**, Singh JA, Tugwell P et al. OMERACT development of a core domain set of outcomes for shared decision making interventions: *J Rheumatol*. 2019 Feb 1. pii: jrheum.181071. doi: 10.3899/jrheum.181071. [Epub ahead of print]
135. **Tsao NW**, Lynd LD, **Sayre EC**, Sadatsafavi M, Hanley G, **De Vera MA**. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. *BMJ Open*. 2019 Feb 20;9(2):e023714.
136. Tsuchiya A, **Bansback N**, Hole AR, Mulhern B. Manipulating the 5 dimensions of the EuroQol instrument: the effects on self-reporting actual health and valuing hypothetical health states. *Med Decis Making*. 2019 May;39(4):379-392.
137. Tworek KB, Ickert C, Bakal J, Eliasziw M, Wagg AS, **Jones CA**, Slaughter SE. Examining the impact of knowledge translation interventions on uptake of evidence-based practices by care aides in continuing care. *Worldviews Evid Based Nurs*. 2019 Feb;16(1):21-28.
138. Unlu O, Erkan D, Barbhैया M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, **Fortin PR** et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. *Arthritis Care Res (Hoboken)*. 2019 Jan; 71 (1):134-141.
139. Vallerand IA, Lewinson RT, Frolkis AD, Lowerison MW, Kaplan GG, Swain MG, Bulloch AGM, Patten SB, **Barnabe C**. Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study. *RMD Open*. 2018 Jul 11;4(2):e000670.
140. Vallerand IA, Patten SB, **Barnabe C**. Depression and the risk of rheumatoid arthritis. *Curr Opin Rheumatol*. 2019 May;31(3):279-284.
141. Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, **Barnabe C**, Patten SB. Assessment of a bidirectional association between major depressive disorder and alopecia areata. *JAMA Dermatol*. 2019 Jan 16. doi: 10.1001/jamadermatol.2018.4398. [Epub ahead of print].
142. Verstappen SMM, **Lacaille D**, Boonen A et al. Considerations for evaluating and recommending worker productivity outcome measures: an update from the OMERACT Worker Productivity Group. *J Rheumatol*. 2019 Apr 1. pii: jrheum.181201. doi: 10.3899/jrheum.181201. [Epub ahead of print].

143. Wallace ZS, Zhang Y, Perugino CA, Naden R, **Choi HK**, Stone JH; ACR/EULAR IgG4-RD Classification Criteria Committee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. *Ann Rheum Dis*. 2019 Mar;78(3):406-412.
144. Waterson HB, Whitehouse MR, **Greidanus NV**, **Garbuz DS**, Masri BA, Duncan CP. Revision for adverse local tissue reaction following metal-on-polyethylene total hip arthroplasty is associated with a high risk of early major complications. *Bone Joint J*. 2018 Jun 1;100-B(6):720-724.
145. Wei J, Gross D, Lane NE, **Lu N**, Wang M, Zeng C, Yang T, Lei G, **Choi HK**, Zhang Y. Risk factor heterogeneity for medial and lateral compartment knee osteoarthritis: analysis of two prospective cohorts. *Osteoarthritis Cartilage*. 2019 Apr;27(4):603-610.
146. Wei J, Neogi T, Terkeltaub R, Fenves AZ, Zeng C, Misra D, **Choi HK**, Lei G, Zhang Y. Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study. *Osteoarthritis Cartilage*. 2019 Jun 8. pii: S1063-4584(19)31068-4.
147. Wells GA, Smith C, Hossain A, Karsh J, Singh J, **Hazlewood G**, Tugwell P. Drugs for the management of rheumatoid arthritis: clinical evaluation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018. Book
148. Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, **Fortin PR**, et al. Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort. *J Rheumatol*. 2019 May;46(5):492-500.
149. Wither JE, Prokopec SD, Noamani B, Chang NH, Bonilla D, Touma Z, Avila-Casado C, Reich HN, Scholey J, **Fortin PR**, Boutros PC, Landolt-Marticorena C. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: clinical/pathologic associations and etiologic mechanisms. *PLoS One*. 2018 May 9;13(5):e0196117.
150. Wordsworth S, Doble B, Payne K, Buchanan J, **Marshall DA**, McCabe C, Regier DA. Using 'big' data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. *Value in Health*, September 2018; 21(9):1048-1053.
151. **Xie H**, Gao W, Xing B, Heitjan D, Hedeker D, Yuan C. Measuring the impact of nonignorable missingness using the R Package isni. *Computer Methods and Programs in Biomedicine*. 2018 Oct;164:207-220.
152. Zeng C, Dubreuil M, LaRochelle MR, **Lu N**, Wei J, **Choi HK**, Lei G, Zhang Y. Association of tramadol with all-cause mortality among patients with osteoarthritis. *JAMA*. 2019 Mar 12;321(10):969-982.
153. Zeng C, Lane NE, Hunter DJ, Wei J, **Choi HK**, McAlindon TE, Li H, **Lu N**, Lei G, Zhang Y. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. *Osteoarthritis Cartilage*. 2019 Jun;27(6):855-862.



## Appendix II

### ABSTRACTS

1. Amlani A, Tarnopolsky M, Brady L, Garcia de la Torre I, Mahler M, **Choi M**, Fritzler MJ. Anti-NT5c1A Autoantibodies as biomarkers in inclusion body myositis. *Arthritis Rheum.* 2018;70(Suppl 9):1473-74.
2. Aringer M, Costenbader K, Brinks R, Boumpas D, Daikh D, Jayne D, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Diamond B, Jacobsen S, McCune WJ, Ruiz-Irastorza G, Schneider M, Urowitz M, Bertsias G, **Clarke AE**, et al. Validation of new systemic lupus erythematosus classification criteria. *Arthritis Rheum.* 2018;70(Suppl 9):3300-301.
3. **Atiquzzaman M**, Karim E, Wong H, **Kopec J**, **De Vera M**, **Anis A**. Comparative cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) among individuals with osteoarthritis; findings from Provincial prescription claim records in British Columbia, Canada. *EULAR. Ann Rheum Dis.*2019;78(Suppl 2):A1394.
4. **Aviña-Zubieta JA**, **Haag HD**, **Sayre EC**, **Esdaile JM**, **De Vera MA**. Adherence to antimalarials and risk of type 2 diabetes mellitus in patients with systemic lupus erythematosus: a population-based cohort study. *Lupus Science & Medicine.* Aug 2018, 5 (Suppl 2) A14-A15.
5. **Choi M**, Campbell E, **Clarke AE**, Amlani A, Jung M, **Barber C**, St Pierre Y, Fritzler M. Anti-NT5c1A autoantibodies in systemic lupus erythematosus. *Lupus Science & Medicine* 2019;6(Suppl 1):A8.
6. **Choi M**, **Clarke AE**, Jung M, **Barber C**, St Pierre Y, Mahler M, Fritzler M. Clinical and serological correlations of autoantibodies directed against RNP-C in systemic lupus erythematosus. *Lupus Science & Medicine* 2019;6(Suppl 1):A115.
7. **Choi M**, **Clarke AE**, Chin A, Jung M, **Barber C**, Fritzler M. Anti-neutrophil cytoplasmic antibodies in lupus nephritis. *Lupus Science & Medicine* 2019;6(Suppl 1):A15.
8. **Avina-Zubieta JA**, **Li G**, **Lu L**, **Esdaile J**, **Xie H**. Increased mortality among patients with systemic lupus erythematosus after hydroxychloroquine discontinuation. *Lupus Science & Medicine* 2019;6(Suppl 1):A217.
9. **Aviña-Zubieta JA**, **Li L**, **Lu N**, **Esdaile J**, **Choi H**, **Xie H**. Risk of hip fracture among patients with newly diagnosis of systemic lupus erythematosus. a population-based study. *Lupus Science & Medicine* 2019;6(Suppl 1):A55.
10. **Bansback N**, Curtis J, Huang J, Lewis L, Johansson T, Michaud K, Liao KP. Patterns of biosimilar use in the rheumatology informatics system for effectiveness (RISE) Registry. *Arthritis Rheum.* 2018;70(Suppl 9):2109-10.
11. **Bansback N**, **Koehn CL**, Chiu J, Mulder M, **Li L**. Access to prescription drugs in Canada: results from an online survey. *Arthritis Rheum.* 2018;70(Suppl 9):2413.

12. Barbacki A, Petri M, **Avina-Zubieta JA**, Alarcon G, Bernatsky S. Fatigue measurements in systemic lupus erythematosus. *Arthritis Rheum.* 2018;70(Suppl 9):1846-48.
13. **Barber CE, Lacaille D**, Hall M, Bohm V, Rankin J, **Barnabe C, Hazlewood G, Marshall D, Li L, English K, Tsui K**, Homik J, Mosher D, MacMullan P, Then K. Developing a patient-centered balanced scorecard for quality of care in rheumatoid arthritis: vision and strategic objectives. *J Rheumatol.* 2019;46(7):79.
14. **Barber CE**, Bohm V, Then K, Hall M, **Marshall D**, Rankin J, **Tsui K, Barnabe C, Hazlewood G, English K**, Mosher D, **Li L**, Homik J, MacMullan P, **Lacaille D**. A patient-centered balanced scorecard for rheumatoid arthritis: selecting the performance measures. *J Rheumatol.* 2019;46(7):43-44.
15. **Barber CE, Lacaille D**, Faris P, Mosher D, Katz S, Homik J, Patel J, Zhang S, Yee K, **Barnabe C, Hazlewood G**, Bykerk V, Shiff N, Twilt M, Ahluwalia V, Burt J, **Benseler S**, Thorne C, **Marshall D**. Reporting of Arthritis Alliance of Canada System-Level Performance Measures for patients with rheumatoid arthritis in Alberta. *J Rheumatol.* 2019;46(7):45.
16. **Barber C, Lacaille D**, Faris P, Mosher DP, Katz S, Homik J, Patel J, Zhang S, **Barnabe C, Hazlewood G**, Ahluwalia V, Shiff N, Bykerk VP, Twilt M, **Benseler S**, Burt J, **Marshall DA**. Evaluation of performance measures reveals delays and sub-optimal access to rheumatology care and treatment. *Arthritis Rheum.* 2018;70(Suppl 9):3336-37.
17. **Barber M**, St. Pierre Y, Urowitz M, Gladman D, Bernatsky S, Vinet E, Pineau C, Hanly J, Peschken C, **Fortin P**, Jung M, **Barber CE**, Elliott S, **Clarke A**. Self-reported indirect costs are underestimated in a Canadian cohort of patients with systemic lupus erythematosus (SLE). *J Rheumatol.* 2019;46(7):81.
18. **Barnabe C**, Miller J, Teare S, Eaglespeaker C, Roland B, Calling Last S, Eshkakogan N, Crowshoe L, **Lopatina E, Marshall DA**. Experiences of urban First Nations and Métis patients accessing and navigating the health system for inflammatory arthritis care. *Arthritis Rheum.* 2018;70(Suppl 9):1293.
19. **Barnabe C**, Kherani R, Appleton T, Henderson R, Crowshoe L. Participant-reported effect of an Indigenous Health continuous professional development education initiative. *Arthritis Rheum.* 2018;70(Suppl 9):196.
20. **Barnabe C**, Martin L, Kaplan G, Beck P. Environmental exposures associated with the requirement for biologic therapy in rheumatoid arthritis. *J Rheumatol.* 2019;46(7):37.
21. **Barnabe C**, Kherani R, Appleton T, Henderson R, Crowshoe L. Participant-reported effect of an Indigenous health continuous professional development education initiative. *J Rheumatol.* 2019;46(7):36.



22. **Bartlett SJ**, Schier O, Valois MF, Hitchon C, Bessette L, Boire G, Thorne C, Pope JE, Bykerk VP, Keystone EC, Tin D, **Hazlewood G**. Lifestyle and MTX use are the strongest predictors of not achieving remission in the first year of rheumatoid arthritis: results from the Canadian Early Arthritis Cohort (CATCH). *Arthritis Rheum*. 2018;70(Suppl 9):3364-65.
23. **Bartlett S**, Schieir O, Valois MF, Boire G, Hitchon C, Pope J, Tin D, Thorne C, Bessette L, Keystone E, **Hazlewood G**, Bykerk V. Lifestyle and no methotrexate (MTX) are the strongest predictors for failing to reach remission in the first year of rheumatoid arthritis: results from the Canadian Early Arthritis Cohort (CATCH). *J Rheumatol*. 2019;46(7):95-96.
24. Boyeva V, Alabsi H, Seidman M, Paterson R, Kur J, Chang S, Chen L, **Carruthers M**. Rituximab in idiopathic retroperitoneal fibrosis. *Arthritis Rheum*. 2018;70(Suppl 9):392.
25. Brunet S, Manske S, Engelke K, Boyd SK, **Barnabe C**. Joint repair while initiating biologic therapy in rheumatoid arthritis. *Arthritis Rheum*. 2018;70(Suppl 9):2439-40.
26. Brunet S, Manske SL, Boyd SK, **Barnabe C**. Joint repair while initiating biologic therapy in rheumatoid arthritis. *J Rheumatol*. 2019;46(7):37.
27. Campbell E, Pannu T, Fritzler MJ, Jung M, **Barber C**, St. Pierre Y, **Clarke AE**. Correlation between antibodies to the Phosphatidylserine/Prothrombin Complex (aPS/PT) and Anti- $\beta$ 2glycoprotein-1-Domain 1 (anti- $\beta$ 2GP1-D1) and vascular thrombosis (VT) and/or pregnancy morbidity (PM). *Arthritis Rheum*. 2018;70(Suppl 9):2685-86.
28. **Carruthers M**, Mattman A, Boyeva V, **Cartagena L**, van der Gugten G, Seidman M, Chen L. Serum IgG4 Test characteristics: Immunonephelometry versus liquid chromatography tandem mass spectrometry. *Arthritis Rheum*. 2018;70(Suppl 9):1987.
29. Charlton A, Abu-Hakima M, **Barber CE**. Osteoporosis screening and management in patients with rheumatoid arthritis. *J Rheumatol*. 2019;46(7):87-88.
30. **Charlton JM**, **Kobsar D**, **Hunt MA**. Does dynamic knee adduction angle impact clinical response to a toe-out gait modification intervention. *Osteoarthritis & Cartilage*. 27(Suppl 1):S112-S113.
31. Chen-Xu M, Yokose C, Pillinger M, **Choi HK**. Contemporary comorbidity burden of gout and hyperuricemia in the US during the past decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016). *Arthritis Rheum*. 2018;70(Suppl 9):2470-71.
32. Chen-Xu M, Yokose C, Pillinger M, **Choi HK**. Prevalence of urate-lowering therapy use and target urate level achievement among gout patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014). *Arthritis Rheum*. 2018;70(Suppl 9):2471-72.

33. Chen-Xu M, Yokose C, Pillinger M, **Choi HK**. Contemporary prevalence of gout and hyperuricemia in the United States (National Health and Nutrition Examination Survey [NHANES] 2015-2016) and Decadal Trends (NHANES 2007-2016). *Arthritis Rheum*. 2018;70(Suppl 9):1264-65.
34. **Choi M**, Campbell E, **Clarke AE**, Jung M, **Barber C**, St. Pierre Y, Fritzler MJ. Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in systemic lupus erythematosus. *Arthritis Rheum*. 2018;70(Suppl 9):1886-87.
35. **Choi M**, Campbell E, **Clarke A**, Amlani A, Jung M, **Barber CE**, St. Pierre Y, Fritzler M. Anti- NT5c1A autoantibodies in systemic lupus erythematosus. *J Rheumatol*. 2019;46(7):33.
36. **Choi M**, **Clarke A**, Chin A, Jung M, **Barber CE**, Fritzler M. Anti-neutrophil cytoplasmic antibodies in lupus nephritis. *J Rheumatol*. 2019;46(7):34.
37. **Choi M**, Butler E, **Clarke A**, Skeith L, Ma J. Threatening thrombocytopenias in lupus pregnancies. *J Rheumatol*. 2019;46(7):33-34.
38. **Choi M**, Campbell E, **Clarke AE**, Amlani A, Jung M, **Barber C**, St Pierre Y, Fritzler M. Anti-NT5c1A autoantibodies in systemic lupus erythematosus. *Lupus Science & Medicine* 2019;6(Suppl 1):A8.
39. **Choi M**, **Clarke AE**, Jung M, **Barber C**, St Pierre Y, Mahler M, Fritzler M. Clinical and serological correlations of autoantibodies directed against RNP-C in systemic lupus erythematosus. *Lupus Science & Medicine* 2019;6(Suppl 1):A115.
40. **Choi M**, **Clarke AE**, Chin A, Jung M, **Barber C**, Fritzler M. Anti-neutrophil cytoplasmic antibodies in lupus nephritis. *Lupus Science & Medicine* 2019;6(Suppl 1):A15.
41. **Clarke AE**, Goss T, Piscitello A, Chandra T, O'Malley T, Dervieux T, Powell T. An economic evaluation on the impact of earlier systemic lupus erythematosus (SLE) diagnosis using complement C4d activation products in a multivariate assay panel (MAP). *Arthritis Rheum*. 2018;70(Suppl 9):2414-15.
42. **Clarke AE**, Kabadi S, Durden E, Winer I, Bacani K, Costenbader K, Yazdany J. The economic burden of systemic lupus erythematosus (SLE) within a commercially-insured population in the United States stratified by disease severity. *Arthritis Rheum*. 2018;70(Suppl 9):1297-98.
43. **Clarke AE**, **Barber M**, St Pierre Y, Urowitz M, Gladman D, Bernatsky S, Vinet E, Pineau C, Hanly J, Peschken C, **Fortin P**, Jung M, **Barber C**, Elliot S. Self-reported indirect costs are underestimated in a Canadian cohort of patients with SLE. *Lupus Science & Medicine* 2019;6(Suppl 1):A41.
44. Concha J, Werth VP, Merola JF, Fiorentino D, **Dutz J**, Fujimoto M, Goodfield M, Ang Chia-Chun, Nyberg F, Volc-Platzer B. Developing a classification criteria for cutaneous dermatomyositis utilizing the Delphi Technique. *Arthritis Rheum*. 2018;70(Suppl 9):2540-41.

45. Costenbader K, Kabadi S, Durden E, Winer I, Bacani K, Yazdany J, **Clarke AE**. The economic burden of systemic lupus erythematosus (SLE) within a Medicaid Cohort stratified by disease severity. *Arthritis Rheum*. 2018;70(Suppl 9):3377-78.
46. Davis A, Wong R, Steinhart K, Astephen Wilson J, Cruz L, Cudmore D, Dwyer T, **Li LC**, MacDonald P, Marks P, Nimmon L, Ogilvie-Harris D, Urquhart N, Chahal J. Limiting the risk of osteoarthritis after anterior cruciate ligament injury: are we missing the opportunity to intervene? *Arthritis Rheum*. 2018;70(Suppl 9):430-31.
47. Dalbeth N, Frampton C, Baumgartner S, Fung M, **Choi HK**. Predictors of patient and physician perceptions of gout disease activity. *Arthritis Rheum*. 2018;70(Suppl 9):2599-600.
48. Dalbeth N, Frampton C, Fung M, Baumgartner S, Nicolaou S, **Choi HK**. Construct validity of provisional remission criteria for gout: a dual energy CT study. *Arthritis Rheum*. 2018;70(Suppl 9):2455-56.
49. **Da Costa D**, Neville C, Julier AS, Rochon M, Eng D, Peschken C, Vinet E, Smith CD, Matsos M, Pope JE, **Clarke AE**, Keeling S, **Avina-Zubieta JA**, **Hudson M**, **Fortin PR**. A Pan-Canadian study of factors associated with perceived doctor-patient communication in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2018;70(Suppl 9):2588-89.
50. Deshauer S, Massetto A, Ikic A, Smith D, Robinson D, Fritzler M, Sutton E, Gyger G, **Fortin PR**, **Hudson M**, Baron M, Pope J, Thorne C, Khalidi N, Larche M, Beattie K. Scleroderma and pregnancy: worse pulmonary outcomes following pregnancy in patients from the CSRG Registry. *J Rheumatol*. 2019;46(7):102.
51. **De Vera MA**, **Tsao N**, **Sayre EC**, **Howren A**. Exposure to Disease modifying antirheumatic drugs during pregnancy in women with inflammatory arthritis and the risk of serious maternal infection: a population-based cohort study. *Arthritis Rheum*. 2018;70(Suppl 9):2371-72
52. **Dhiman K**, Stewart A, **Rat AC**, **Rogers P**, Mosher D, **Marshall D**, **Lacaille D**. A qualitative study exploring relevance of the making it work program to osteoarthritis. *J Rheumatol*. 2019;46(7):87.
53. Durand C, Eldoma M, **Marshall DA**, **Hazlewood G**. Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: a systematic review. *Arthritis Rheum*. 2018;70(Suppl 9):2618.
54. Ellingwood L, Schier O, **Bartlett SJ**, Bessette L, Hitchon CA, Boire G, **Hazlewood G**, Keystone EC, Tin D, Thorne C, Bykerk VP, Pope JE. Characterizing palindromic symptoms in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort Study (CATCH). *Arthritis Rheum*. 2018;70(Suppl 9):2727-28.
55. Ellingwood L, Kudaeva F, Schieir O, **Bartlett S**, Bessette L, Hitchon C, Boire G, **Hazlewood G**, Keystone E, Tin D, Thorne C, Bykerk V, Pope J. A comparison of patient versus physician reported symptom onset dates in early rheumatoid arthritis. *J Rheumatol*. 2019;46(7):52.

56. Ellingwood L, Schieir O, **Bartlett S**, Bessette L, Hitchon C, Boire G, **Hazlewood G**, Keystone E, Tin D, Thorne C, Bykerk V, Pope J. Characterizing palindromic symptoms in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort Study. *J Rheumatol*. 2019;46(7):53.
57. **English K, MacDonald G**. Improved quality of life with patient engagement in research. *Arthritis Rheum*. 2018;70(Suppl 9):3417-19.
58. **Esculier JF**, Jarrett M, Krowchuk NM, Rauscher A, Wiggermann V, Taunton JE, Wilson D, Gatti A, **Hunt MA**. Effects of running on knee cartilage in female runners with and without osteoarthritis: a pilot study. *Osteoarthritis & Cartilage*. 27(Suppl 1):S347.
59. **Fortin P**, Neville C, Julien AS, Rochon M, Eng D, Peschken C, Vinet E, **Hudson M**, Smith D, Matsos M, Pope JE, **Clarke AE**, Keeling S, **Avina-Zubieta JA**, **Da Costa D**. Activation towards health self-management in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2018;70(Suppl 9):3009-10.
60. **Fortin PR**, Neville C, Julien A-S, Rahme E, Rochon M, Haroun V, Vinet E, Peschken C, **Clarke A**, Pope J, Keeling SO, **Avina-Zubieta A**, Smith D, Matsos M, **Hudson M**, Young J, Singer W, Morrison A-L, Eng D, **Da Costa D**. Lupus patients do not improve health self-management abilities after a short exposure to MyLupusGuide. *J Rheumatol*. 2019;46(7):100-101.
61. **Fortin PR**, Neville C, Julien AS, Rahme E, Rochon M, Haroun V, Vinet E, Peshken C, **Clarke AE**, Pope, J, Keeling S, **Aviña-Zubieta JA**, Smith D, Matsos M, **Hudson M**, Young J, Morrison AL, Eng D, **DaCosta D**. MyLupusGuide™, a lupus-specific web interactive navigator, improves self-efficacy and activation in patients with low activation and in men. *Lupus Science & Medicine*. 2019;6(Suppl 1):A144.
62. **Fortin PR**, Julien A-S, **Clarke AE**, Pope J, Matsos M, Smith D, Peschken C. The Lupus Severity Index is a predictor of damage and death in lupus patients. *Lupus Science & Medicine*. 2019;6(Suppl 1):A92.
63. **Gukova K, Esdaile JM, Tavakoli H, Avina-Zubieta JA**. Poor rates of screening for retinal toxicity in patients on antimalarial medications: a population-based study. *Arthritis Rheum*. 2018;70(Suppl 9):2409-10.
64. **Hamilton C, Hoens A, McQuitty S, McKinnon A, English K, Backman C, Khodarahmi N, Azimi T, Li L**. The use of patient perspectives to develop and pretest a scale of meaningful patient engagement in health research projects. *Qual Life Res*. 2018;27(Suppl 1):S166.
65. Hanly JG, Li Q, Su L, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, **Fortin PR**, Gladman D, Bruce IN, Petri M. et al. Psychosis in systemic lupus erythematosus: results from an International Inception Cohort Study. *Arthritis Rheum*. 2018;70(Suppl 9):3258-60.

66. Hanly J, Qiuju L, Su L, Urowitz MB, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, **Clarke AE**, Wallace DJ, Isenberg D, Rahman A, Merrill JT, **Fortin PR** et al. Neuropathies in systemic lupus erythematosus: results from an international, inception cohort study. *Ann Rheum Dis.* 2019;78(suppl 2):A206.
67. **Hazlewood G**, Hull P, Sirois A, Bykerk V, Schieir O, **Loyola-Sanchez A, Barnabe C, Barber CE, Marshall D**, Stevenson M, Richards D, Proulx L, **Bartlett S**. Patient perspectives on tapering treatment in rheumatoid arthritis: a qualitative study. *J Rheumatol.* 2019;46(7):49-50.
68. Hawker GA, Ravi B, **Marshall DA**, Dunbar MJ, Bohm E, The BEST knee Study Team. The relationship between pre-operative patient-reported expectations of total knee arthroplasty and satisfaction with surgical outcome at six months. *Osteoarthritis & Cartilage.* 27(Suppl 1):S312.
69. Holdren M, Schieir O, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Bykerk V, Pope J. Residual fatigue in rheumatoid arthritis is less over four years if in remission by three months: results from the CATCH Cohort. *J Rheumatol.* 2019;46(7):64-65.
70. **Howren A, Zusman E, Avina-Zubieta JA, De Vera MA**. The prevalence, incidence, and determinants of depression and anxiety in less common systemic autoimmune rheumatic diseases: a systematic review and meta-analysis. *Arthritis Rheum.* 2018;70(Suppl 9):2391-92.
71. **Howren A, Zusman E, Rai SK, Shojania K, De Vera MA**. The prevalence, incidence, determinants and impacts of depression and anxiety in gout: a systematic review. *Arthritis Rheum.* 2018;70(Suppl 9):1240-41.
72. **Howren A, Avina-Zubieta JA, De Vera MA**. The impact of arthritis on utilization of mental health treatments for comorbid mental disorders: findings from a nationally representative mental health survey. *Ann Rheum Dis.* 2019;78(suppl 2):A1376.
73. Jin X, Al Sayah, Ohinmaa A, **Marshall D**, Johnson J. Responsiveness of the EQ-5D-5L and EQ-5D-3L in patients following total hip or knee replacement. *Qual Life Res.* 2018;27(Suppl 1):S177.
74. Jin X, Al Sayah F, Ohinmaa A, **Marshall D**, Johnson J. EQ-5D-3L vs. EQ-5D-5L: a cross-sectional comparison of measurement properties among total hip and knee replacement patients. *Qual Life Res.* 2018;27(Suppl 1):S61.
75. Jones CE, Qian H, Zhang H, Guo Y, Russell D, Forster BB, Wong H, **Esdaile JM**, Wilson DR, **Cibere J, and the IMPAKT-HiP Study Team**. dGEMRIC is reduced in hips with bone marrow lesions. *IWOIA Program Book.* 2019;OP14:30.
76. Jorge A, **Lu N, Sayre EC, Tavakoli H, McCormick N, Esdaile J, De Vera MA, Choi HK, Avina-Zubieta JA**. Increased mortality among patients with systemic lupus erythematosus after hydroxychloroquine discontinuation. *Arthritis Rheum.* 2018;70(Suppl 9):3261-62.
77. Jorge A, **Lu N**, Wallace Z, **Choi H**. Contemporary prescription opioid use among patients with systemic lupus erythematosus: a population-based cohort study. *Lupus Science & Medicine* 2019;6(Suppl 1):A114.

78. Kaal KJ, **Bansback N, Anis A, Harrison M**. Patient-physician communication about medication costs in rheumatoid arthritis. *Arthritis Rheum*. 2018;70(Suppl 9):2152-53.
79. Kaal J, **Hudson M, Bansback N, Harrison M**. Health care providers' perceptions regarding barriers in the implementation of preventive therapies in rheumatoid arthritis (RA). *J Rheumatol*. 2019;46(7):83-84.
80. **Kaminski J**, Collison J, Lavender L, Price M, Brown M, Roberts K, **Da Costa D**, Adam P, Lehman A, **Li LC, Lacaille D**. Proof-of-concept study of a culturally-sensitive, community based self-management program for First Nations people with arthritis and their families. *J Rheumatol*. 2019;46(7):21.
81. King LK, **Marshall DA**, Hawker GA. Determinants of opioid analgesics use in patients with knee osteoarthritis referred for consideration of total knee arthroplasty. *Osteoarthritis & Cartilage*. 27(Suppl 1):S312.
82. **Kobsar D, Charlton JM**, Krowchuk NM, Thatcher D, **Hunt MA**. Knee-specific gait deviation index for assessing healthy and osteoarthritic gait. *Osteoarthritis Cartilage*. 2019;27(Suppl 1):S119.
83. **Kopec JA**. Compression of morbidity revisited: data from the Global Burden of Disease Study. *Qual Life Res*. 2018;27(Suppl 1):S99.
84. **Kopec JA, Sayre EC, Cibere J, Li LC, Bansback N**, Wong H, **Esdaile JM**. Use of pain medication among persons with osteoarthritis in Canada. *Osteoporosis International* (2019) 30 (Suppl 2):S774.
85. **Kopec JA, Cibere J, Sayre EC, Li LC, Lacaille D, Esdaile JM**. Descriptive epidemiology of musculoskeletal diseases in Canada: data from the Global Burden of Disease Study. *Osteoarthritis Cartilage*. 2019;27(Suppl 1):S259.
86. Kudaeva F, Speechley M, Klar N, Schier O, Bartlett J, Bessette L, Boire G, **Hazlewood G**, Hitchon CA, Keystone EC, Tin D, Thorne C, Bykerk VP, Pope JE. Possible association of early inflammatory arthritis with viral outbreaks such as influenza: time series analysis of the Canadian Early Inflammatory Arthritis Cohort (CATCH). *Arthritis Rheum*. 2018;70(Suppl 9):76-77.
87. Kulhawy-Wibe S, Zell J, Michaud K, Yazdany J, Ehrlich-Jones LS, Thorne C, Everix D, **Barber C**. Cross-cultural validity of functional status assessment measures for rheumatoid arthritis. *Arthritis Rheum*. 2018;70(Suppl 9):353-54.
88. Kuntze G, Lorenzen K, Ronsky J, **Whittaker J**, Emery C. Determining multi-joint biomechanics signatures for youth with an intra-articular knee injury: towards early markers of post-traumatic osteoarthritis. *Osteoarthritis & Cartilage*. 2019;27(Suppl 1):S65-S66.
89. Kuriya B, Schier O, Valois MF, Pope JE, Boire G, Bessette L, Thorne C, Tin D, Hitchon CA, **Hazlewood G, Bartlett SJ**, Keystone EC, Bykerk VP, Barra L. Characteristics of metabolic syndrome in men and women with early rheumatoid arthritis. *Arthritis Rheum*. 2018;70(Suppl 9):531-32.

90. Kuriya B, Schieir O, Valois MF, Pope J, Boire G, Bessette L, **Hazlewood G**, Thorne C, Tin D, Hitchon C, **Bartlett S**, Keystone E, Bykerk V, Barra L. Prevalence and characteristics of metabolic syndrome in men and women with early rheumatoid arthritis. *J Rheumatol.* 2019;46(7):98.
91. **Lacaille D, Kaminski J**, Collison J, Lavender L, Brown M, Roberts K, **Da Costa D**, Adam P, **Li L**, Lehman A. Process evaluation of a culturally-sensitive, community based self-management program for First Nations People with arthritis and their families. *Arthritis Rheum.* 2018;70(Suppl 9):2416-17.
92. Ladouceur A, Bernatsky S, Ramsey-Goldman R, **Clarke AE**. Managing cancer risk in patients with systemic lupus erythematosus. *Expert Rev Clin Immunol.* 2018 Oct;14(10):793-802.
93. Lee R, Sharif B, Vik S, Yee K, Werle J, **Marshall DA**. Association of health determinants with change in patterns of resource use after total knee replacement surgery. *Osteoarthritis Cartilage.* 2019;27(Suppl 1):S301.
94. **Lee-Pii K, Xie H, Zheng Y, Li L, Lacaille D**. Physical activity in people living with rheumatoid arthritis compared to general population controls. *J Rheumatol.* 2019;46(7):21-22.
95. **Leese J, Zhu S, Macdonald G, Pourrahmat MM, Townsend AF, Backman CL, Nimmon L, Li L**. Emerging ethical issues in physical activity monitoring of persons living with arthritis: a qualitative evidence synthesis. *Arthritis Rheum.* 2018;70(Suppl 9):2593-94.
96. **Leese J, Geldman J, Zhu S, Macdonald GG, Pourrahmat M, Townsend A, Backman C, Nimmon L, Li LC**. Using physical activity wearables in self-management from the perspectives of persons living with arthritis: a qualitative evidence synthesis. *J Rheumatol.* 2019;46(7):23.
97. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill JT, Ginzler EM, **Fortin PR** et al. Construction and validation of a frailty index as a novel health measure in systemic lupus erythematosus. *Arthritis Rheum.* 2018;70(Suppl 9):1851-52.
98. **Le CY**, Hui C, Emery CA, Manns P, **Whittaker JL**. Variation in the recovery of knee-related quality of life following anterior cruciate ligament reconstruction in young athletes. *Osteoarthritis Cartilage.* 2019;27(Suppl 1):S442.
99. Lewinson R, Vallerand I, LaMothe J, Parsons L, Frolkis A, Lowerison M, Patten **S, Barnabe C**. Increasing rates of arthroplasty for psoriatic arthritis in the United Kingdom between 1995 and 2010. *Arthritis Rheum.* 2018;70(Suppl 9):699-700.
100. **Li L, Xie H, Lu N, Esdaile J, Avina-Zubieta JA**. The impact of systemic lupus erythematosus on the risk of newly diagnosed hip fracture: a population-based study. *J Rheumatol.* 2019;46(7):25-26.

101. **Lu N**, Yokose C, **Xie H**, **Li G**, **Rai SK**, Kim SC, **Choi HK**. Cardiovascular disease, other purported risk factors, and allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. *Arthritis Rheum*. 2018;70(Suppl 9):2486-87.
102. **Luquini Pereira LA**, Schnurr-Howsam R, **Sayre EC**, **Lacaille D**. Identifying determinants of presenteeism in workers with inflammatory arthritis. *J Rheumatol*. 2019;46(7):23.
103. **Luquini A**, Schnurr-Howsam R, **Sayre EC**, **Lacaille D**. Identifying determinants of presenteeism in workers with inflammatory arthritis. *Ann Rheum Dis*. 2019;78(suppl 2):A1378.
104. Lundon K, Shupak R, Inrig T, Paton M, Kennedy C, McGlynn M, **Barber CE**. Measuring advanced/extended practice roles in arthritis and musculoskeletal care in Canada: Stand Up and be Counted Too (2)! *J Rheumatol*. 2019;46(7):82.
105. Mahler M, Bentow C, Milo J, **Hudson M**, Baron M, **Choi M**, Fritzler MJ. Identification of an immunodominant epitope on Rnpc-3 as a target of autoantibodies in patients with systemic sclerosis. *Arthritis Rheum*. 2018;70(Suppl 9):880-881.
106. Marks C, Bernatsky S, Pope J, Thorne C, Ling V, **Barber CEH**, Kuriya B, Paterson M, Widdifield J. The effect of physician sex on practice sizes, volumes, and physician remuneration: a population-based longitudinal evaluation of male versus female rheumatologists in Ontario. *J Rheumatol*. 2019;46(7):40-41.
107. **Marshall D**, Faris P, Chen G, Patel J, Mosher D, Homik J, Katz S, O'Donnell S, **Barnabe C**, **Lopatina E**, **Barber C**. Determination of rheumatoid arthritis incidence and prevalence in Alberta to measure system performance and plan health services. *J Rheumatol*. 2019;46(7):42.
108. **Marshall D**, Faris P, Mosher D, Katz S, Homik J, Yee K, Zhang S, Patel J, **Barnabe C**, **Barber CE**. Regional variation in system-level performance measures for rheumatoid arthritis in Alberta. *J Rheumatol*. 2019;46(7):23.
109. **Marshall D**, Faris P, Mosher D, Katz S, Homik J, Zhang S, Yee K, Patel J, **Barnabe C**, **Barber CE**. Key performance indicators help track centralized intake processes to optimize early inflammatory arthritis care. *J Rheumatol*. 2019;46(7):44.
110. **Marshall D**, Ortiz M, Patel J, Miller J, Teare S, **Barber C**, Carr E. Co-design of a patient experience survey for arthritis central intake: an example of meaningful patient engagement in healthcare design. *J Rheumatol*. 2019;46(7):42.
111. **Marshall D**, Ortiz M, **Barber C**, Mosher D, Patel J, Katz S, Homik J, Robert J, Miller J, Teare S, Lupton T, Carr E. System evaluation of arthritis central intake for referral of patients with arthritis to specialists. *J Rheumatol*. 2019;46(7):41-42.
112. **Marshall DA**, Currie GR, **Whittaker J**, Emery CA. Matched comparison of health care use and costs 3-10 years after a youth sport-related knee injury. *Osteoarthritis Cartilage*. 27(Suppl 1):S296-S297.



113. **Marshall DA.** What are patient preferences, how do you measure patient preferences and how can I apply them in clinical practice for patients? *Osteoarthritis & Cartilage.* 27(Suppl 1):S15-S16.
114. Sharif B, Zaerpour F, **Marshall D.** Health system expenditures on osteoarthritis across distinct care pathways in Alberta from 2018 to 2025. *Osteoarthritis Cartilage.* 2019;27(Suppl 1):S304-305.
115. **McCormick N, Hamilton C, Koehn CL, English K,** Stordy A, **Li LC.** Canadians' views about using big data in health research from a national online survey: a partnership of patient-consumers and researchers. *Arthritis Rheum.* 2018;70(Suppl 9):1281-82.
116. Neogi T, Peloquin C, Zhang Y, **Choi HK,** Terkeltaub R, Felson DT. Proton Pump Inhibitors and risk of Calcium Pyrophosphate Deposition (CPPD) in a population-based study. *Arthritis Rheum.* 2018;70(Suppl 9):2456-57.
117. Neville A, Dayan N, **Barnabe C,** Elliott S, Proulx L, **Da Costa D,** Bernatsky S, Vinet E. Needs and barriers to pregnancy counselling in women with systemic lupus erythematosus. *Arthritis Rheum.* 2018;70(Suppl 9):2701-02.
118. Ortel T, Meleth S, Catellier D, Crowther M, Erkan D, **Fortin PR,** Garcia D, Haywood N, Levine SR, Phillips MJ, Whitehead N. Recurrent thrombosis in patients with antiphospholipid antibodies following an initial venous or arterial thromboembolic event. *Arthritis Rheum.* 2018;70(Suppl 9):175-76.
119. Pokharel G, Deardon R, **Barnabe C,** Bykerk VP, **Bartlett S,** Bessette L, Boire G, Hitchon C, Keystone EC, Pope J, Tin D, Thorne C, **Hazlewood G.** Combining observational and randomized controlled trial data evidence to jointly estimate remission and response for biologic and non-biologic therapies in rheumatoid arthritis: a bivariate network meta-analysis. *Arthritis Rheum.* 2018;70(Suppl 9):656-58.
120. Pokharel G, Deardon R, Johnson S, Tomlinson GA, **Hazlewood G.** Rheumatologist's beliefs in the effectiveness of other methotrexate-based treatment approaches may explain the low use of triple therapy: a bayesian belief elicitation. *Arthritis Rheum.* 2018;70(Suppl 9):655-56.
121. Porter A, Mirizio E, Fritzler MJ, Brown R, **Choi M,** Schollaert-Fitch K, Liu C, Torok KS. Autoantibody testing in pediatric localized scleroderma (LS). *Arthritis Rheum.* 2018;70(Suppl 9):1563-64.
122. **Rai SK, Lu N,** Yokose C, **Choi HK.** Preventing a large majority of incident gout cases by modifying key risk factors: findings from a prospective cohort of 44,629 men over 26 years. *Arthritis Rheum.* 2018;70(Suppl 9):969.
123. **Rat AC,** Stewart A, **Rogers P,** Mosher DP, **Lacaille D.** Challenges and barriers to employment that persons with osteoarthritis face at work due to their condition. *Arthritis Rheum.* 2018;70(Suppl 9):297-98.
124. Sanders S, Della Torre E, Perugino CA, Long A, **Choi HK,** Stone JH, Wallace Z. Salivary gland disease in IgG4-Related disease is associated with allergic histories. *Arthritis Rheum.* 2018;70(Suppl 9):1985-87.

125. Sevim E, Unlu O, Andrade D, Banzato A, Tektonidou M, Ugarte A, Gerosa M, Cohen H, Branch D, Ramires de Jesus G, Tincani A, **Fortin PR** et al. First and recurrent thrombosis risk after 1897 patient-years of follow-up: prospective results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”). *Arthritis Rheum.* 2018;70(Suppl 9):943-45.
126. Sevim E, Zisa DF, Andrade D, Pengo V, Tektonidou M, Ugarte A, Gerosa M, Ji L, Efthymiou M, Ramires de Jesus G, Branch D, Nalli C, Sciascia S, Belmont HM, **Fortin PR** et al. Clinical and laboratory characteristics of persistently Antiphospholipid Antibody Positive patients: retrospective results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”). *Arthritis Rheum.* 2018;70(Suppl 9):167-68.
127. **Szlachetka T, Li L**, Liu-Ambrose T, **Xie H, Lacaille D**. Systematic review of studies reporting on cognitive function in rheumatoid arthritis compared to the general population. *J Rheumatol.* 2019;46(7):20.
128. **Szlachetka T, Yazdani K, Li L**, Liu-Ambrose T, **Xie H, Lacaille D**. Systematic review of studies reporting on cognitive function in rheumatoid arthritis compared to the general population. Presented at European Congress of Rheumatology (EULAR), June 12 – 15, 2019, Madrid, Spain. *Ann Rheum Dis.* 2019;78(suppl 2):A1598
129. Smith I, Wei J, Zhang Y, **Choi HK**, Bolster M. Alcohol consumption and the risk of coronary heart disease and mortality in patients with rheumatoid arthritis. *Arthritis Rheum.* 2018;70(Suppl 9):3168-69.
130. Sparks JA, Yoshida K, Lin TC, Camargo C, Raby B, **Choi HK**, Barbhuiya M, Tedeschi SK, Lu B, Costenbader K, Karlson E. Causal inference methods for the effect of rheumatoid arthritis on mortality independent of lifestyle and clinical factors before and after rheumatoid arthritis diagnosis. *Arthritis Rheum.* 2018;70(Suppl 9):1050-51.
131. Tan J, **Avina-Zubieta JA**, Dominique A, **Tavakoli H**, Simon TA. Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the Province of British Columbia. *Arthritis Rheum.* 2018;70(Suppl 9):1754-55.
132. Tatangelo M, Tomlinson G, Paterson M, **Bansback N**, Gomes T, Kopp A, Ahluwalia V, Bombardier C. The effect of patient, prescriber and region on the initiation of first biologic for rheumatoid arthritis: a longitudinal population study. *Arthritis Rheum.* 2018;70(Suppl 9):289-290.
133. Taylor DC, Jaffe D, Hoshen M, Shefer G, Bachrach A, Feldman B, Fu AC, **Choi HK**. Is the serum uric acid therapeutic target protective of chronic kidney disease, cardiovascular disease, and mortality for patients with gout? A longitudinal study. *Arthritis Rheum.* 2018;70(Suppl 9):965-67.

134. Tessier-Cloutier B, Twa D, Baecklund E, Gascoyne R, Johnson NA, Backlin C, Kamen DL, **Clarke AE** et al. Cell-of-origin in diffuse large B-Cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. *Lupus Sci Med*. 2019 May 4;6(1):e000324.
135. Toupin-April K, Stinson J, Huber A, and **Fortin P**, Tugwell P et al. Exploring decision making needs about pain management among adolescents with juvenile idiopathic arthritis and their families: preliminary results from interviews. *Arthritis Rheum*. 2018;70(Suppl 9):2589-90.
136. Toupin-April K, Barton, J, Fraenkel L, **Li LC**, and **Bartlett S** et al. Development of a core domain set to assess shared decision making interventions in rheumatology: an OMERACT White Paper to facilitate endorsement. *Arthritis Rheum*. 2018;70(Suppl 9):1381-82.
137. **Truong LK**, Mosewich A, Holt C, **Le CY**, Miciak M, **Whittaker JL**. The influence of psychological, social and contextual factors on recovery following a sport-related knee injury: a scoping review. *Osteoarthritis Cartilage*. 2019;27(Suppl 1):S449-450.
138. Wade N, **De Vera MA**, **Sayre EC**, **Avina-Zubieta JA**. Jorge A, **Lu N**, **Sayre EC**, **Tavakoli H**, **McCormick N**, **Esdaile J**, **De Vera MA**, **Choi HK**, **Avina-Zubieta JA**. Pregnancy outcomes in systemic lupus erythematosus and pre-systemic lupus erythematosus: a population-based cohort study. *Arthritis Rheum*. 2018;70(Suppl 9):2672-73.
139. Wallace Z, Stone JH, **Choi HK**. Identifying ANCA-associated vasculitis cases in electronic health records using natural language processing. *Arthritis Rheum*. 2018;70(Suppl 9):3073-74.
140. Wallace Z, Zhang Y, Perugino CA, Naden RP, **Choi HK**, Stone JH. Phenotypic subgroups in IgG4-Related disease – a cluster analysis. *Arthritis Rheum*. 2018;70(Suppl 9):2102-03.
141. Wallace Z, Zhang Y, Stone JH, **Choi HK**. Interstitial lung disease in ANCA-Associated Vasculitis defines a unique subgroup of patients at high risk for respiratory death: a cluster analysis. *Arthritis Rheum*. 2018;70(Suppl 9):1948-49.
142. Wallwork R, **Choi HK**, Perugino CA, Zhang Y, Stone JH, Wallace Z. Cigarette smoking is a risk factor for IgG4-related disease. *Arthritis Rheum*. 2018;70(Suppl 9):1984-85.
143. Wei J, Zeng C, Uyen Sa, Nguyen DT, **Choi HK**, Zhang Y. Racial disparities in utilization of knee replacement: data from the Osteoarthritis Initiative. *Arthritis Rheum*. 2018;70(Suppl 9):3203-04.
144. **Whittaker JL**, Jaremko JL, Emery CA. The applicability of criteria for early osteoarthritis in 'at-risk' post traumatic knee injured and uninjured youth *Osteoarthritis Cartilage*. 2019;27(Suppl 1):S261-262.
145. **Whittaker JL**, Blaney T, Emery CA, Kuntze G, Ronsky JL, Jaremko J. Do tibiofemoral joint shape and alignment differ between youth at increased risk of knee post-traumatic osteoarthritis following a sport-related knee injury and uninjured controls? *Osteoarthritis Cartilage*. 2019;27(Suppl 1):S350-352.

146. Xia H, **Charlton JM, Hunt MA**, Shull P. Preliminary test of a smart shoe for training foot progression angle during walking. World Congress of Osteoarthritis Meeting, Toronto, ON, May 2 – 5, 2019. *Osteoarthritis & Cartilage*. 27(Suppl 1):S64-S65.
147. **Yazdani K, Xie H, Avina-Zubieta JA, Zheng Y, Abrahamowicz M, Lacaille D**. Secular trends in the incident risk of myocardial infarction in rheumatoid arthritis relative to general population. *Ann Rheum Dis*. 2019;78(suppl 2):A328.
148. **Yazdani K, Xie H, Avina-Zubieta JA, Zheng Y, Abrahamowicz M, Lacaille D**. Secular trends in the incident risk of cerebrovascular accidents in rheumatoid arthritis relative to general population. *Ann Rheum Dis*. 2019;78(suppl 2):A328.
149. Yokose C, Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Simeone J, **Choi HK**. Monosodium urate deposition distribution in the knees, hands, and feet of treated gout patients: a dual-energy CT study. *Arthritis Rheum*. 2018;70(Suppl 9):2469-70.
150. Yokose C, Zhang Y, Dalbeth N, Wei J, Nicolaou S, Baumgartner S, Hu J, Fung M, **Choi HK**. A Prospective study examining the prevalence of CT erosions in the feet and ankles of patients with gout treated with allopurinol. *Arthritis Rheum*. 2018;70(Suppl 9):1398-99.
151. Yokose C, Zhang Y, Dalbeth N, Wei J, Nicolaou S, Baumgartner S, Hu J, Fung M, **Choi HK**. Patterns of monosodium urate deposition on dual-energy CT in gout patients on urate-lowering therapy. *Arthritis Rheum*. 2018;70(Suppl 9):959-960.
152. Yu S, Pineda E, Liao I-C, Copeland L, Godley P, **Barber CE**. Predictors and incidence of cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol*. 2019;46(7):78-79.
153. Zhang Y, Wei J, Yokose C, **Rai SK, Choi HK**. Chronic risk factors for recurrent gout flares among established gout patients: a prospective cohort analysis. *Arthritis Rheum*. 2018;70(Suppl 9):1242-43.
154. Zheng B, Wang M, **Hudson M**, Baron M, **Fortin PR**, Canadian Scleroderma Research Group (CSRG). Immunosuppression in diffuse systemic sclerosis improves outcomes using a novel composite response index. *J Rheumatol*. 2019;46(7):60-61.
155. **Zusman E, Howren A, Dutz J, De Vera MA**. Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis. *Arthritis Rheum*. 2018;70(Suppl 9):1831-32.